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Abstract 
Background: Tendinopathy, a general condition of tendon disorder, is common among 
people specially athletes and workers. Tendinosis, an asymptomatic tendon degeneration 
without inflammation, is a frequent form of tendinopathy which can be chronic and 
difficult to successfully treat in long term. The focus of this research study is on this type 
of tendinopathy. The proper strategy to prevent or treat chronic tendinopathy (CT) is still 
unclear.  Understanding the pathology behind CT may help finding proper treatments. 
Although significant advances have been made to understand the tendinopathy 
mechanisms, this condition is still poorly understood.  
Studying CT not only is necessary in order to provide further information about etiology 
and pathogenesis, but also to improve healing strategies. Although many treatment 
strategies have been suggested for CT disorders, none of them has satisfying results.  
Subject: Therefore, the main subject of this study was to characterize a CT model ex vivo, 
which represents the level of degeneration which is not too early to be diagnosed and not 
too late to be treated. This is a transient stage between early and advanced tendinopathy. 
We refer to this stage as moderate tendinopathy. 
After creating moderate tendinopathy, the efficacy of two existing treatments, i.e. matrix 
metalloproteinase inhibitor (MMPI) and platelet-rich-plasma (PRP) injections, in 
combination and alone, on healing moderate tendinopathy model was investigated. 
Methods: The ex vivo model was characterized by using stress deprivation. Rat tail 
tendons (RTTs) were cultured without loading for 0 (control), 2, 4, 6, or 10 days. RTTs 
were subjected to traction testing as well as to histopathological, biochemical, and viability 
assays at the end of their culture time. Then, the ex vivo moderate tendinopathy model was 
further cultured for 6 days with or without receiving treatment(s). The treatments 
included low static loading, alone or in combination with: narrow spectrum MMPI (NI), 
broad spectrum MMPI (BI), PRP, PRP + NI, PRP + BI. Again, RTTs were subjected to traction 
viii 
testing as well as histopathological, biochemical, and viability assays at the end of their 
culture time.  
Results: There were moderate degradative changes in the properties of RTTs at day 4 of 
SD. They included: increases in the space between fibers, cell density, and collagen 
tortuosity as well as a decrease in collagen density and elongation of cell nuclei. No 
changes in the stress at failure of RTTs were observed at this time point. Advance 
degradative changes occurred at later time points, i.e. at days 6 and 10 of SD. They 
included: more increases in the space between fibers, and collagen tortuosity as well as a 
decrease in collagen density and elongation of cell nuclei. There was also a significant 
decrease in stress at failure of RTTs at days 6 and 10 of SD compared to fresh tendons.  
Moreover, our results showed that PRP + NI added to low static loading, improved 
mechanical and histological properties of moderately damaged tendons comparing to 
other treatments, or untreated tendons. Stress at failure of RTTs treated with PRP + NI 
was improved comparing to 10-day SD tendons (p=0.01). PRP + NI also improved fiber 
density, nucleus shape, and space between fibers of RTTs when compared to 10-day SD 
RTTs (p<0.05).  
Conclusions: The simple ex vivo model characterized in this study is useful to study the 
progression of CT, and to investigate the efficacy of potential treatments to stop or reverse 
the progression of the pathology. Moreover, using this model, we have introduced PRP and 
NI combination therapy as a potentially efficient treatment for CT. 
Key words: tendinopathy, stress deprivation, matrix metalloproteinase inhibitor, platelet-
rich-plasma. 
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Résumé 
Contexte: La tendinopathie, une condition générale qui affecte le tendon, est fréquente, 
spécialement chez les athlètes et les travailleurs. La tendinose, une dégénérescence du 
tendon sans inflammation, est une forme fréquente de tendinopathie qui peut être 
chronique et difficile à traiter à long terme. Cette étude est axée sur ce type de 
tendinopathie. La stratégie appropriée pour prévenir ou traiter la tendinopathie 
chronique (TC) n'est toujours pas claire. Mieux comprendre la pathologie de la TC 
contribuera à améliorer les traitements appropriés. Bien que des progrès significatifs 
aient été réalisés pour comprendre les mécanismes de tendinopathie, cette condition est 
encore mal comprise. 
L'étude de la TC n'est pas seulement nécessaire pour fournir de plus amples informations 
sur l'étiologie et la pathogenèse, mais aussi pour améliorer les stratégies de guérison. Bien 
que de nombreuses stratégies de traitement aient été suggérées pour la TC, aucune n’a 
donné de résultats satisfaisants. 
Objet: L'objet principal de cette étude était donc de caractériser un modèle ex vivo de TC, 
qui représente le niveau de dégénérescence qui n'est pas trop précoce pour être 
diagnostiqué et pas trop avancé pour être traité. C'est un stade transitoire entre les 
tendinopathies précoces et avancées. Nous appelons ce stade tendinopathie modérée. 
Après avoir créé une tendinopathie modérée, l'efficacité de deux traitements existants, à 
savoir l’ajout d'inhibiteurs de métalloprotéinases de la matrice (IMPMs) et de plasma riche 
en plaquettes (PRP), en combinaison et individuellement, sur le modèle de tendinopathie 
modérée a été étudiée. 
Méthodes: Le modèle ex vivo créé par la privation de charge mécanique a été caractérisé. 
Les tendons de queue de rat (TQRs) ont été cultivés en absence de charge mécanique 
pendant 0 (témoin), 2, 4, 6 ou 10 jours. Les TQRs ont été soumis à des tests de traction 
ainsi qu'à des analyses histogiques, biochimiques et de viabilité à la fin de leur temps de 
culture. Ensuite, le modèle de tendinopathie modérée ex vivo a été cultivé pendant 6 jours 
x 
avec ou sans traitement. Les traitements comprenaient une faible charge statique, seule 
ou en combinaison avec: IMPM à spectre étroit (IÉ), IMPM à large spectre (IL), PRP, PRP + 
IÉ, PRP + IL. Encore une fois, les TQRs ont été soumis à des tests de traction ainsi qu'à des 
analyses histologiques, biochimiques et de viabilité à la fin de leur temps de culture. 
Résultats: Il y avait des changements modérés dans les propriétés des TQRs au jour 4 de 
la privation de chargement mécanique. Ils comprenaient : l'augmentation de l'espace 
entre les fibres, de la densité cellulaire et de la tortuosité du collagène, ainsi qu'une 
diminution de la densité du collagène et de l'élongation des noyaux cellulaires. Aucun 
changement dans la contrainte à la rupture des TQRs n'a été observé à ce moment. Les 
changements de dégradation avancés se sont produits à des moments ultérieurs, à savoir 
aux jours 6 et 10 de privation de charge mécanique. Ils comprenaient : une augmentation 
de l'espace entre les fibres et de la tortuosité du collagène, ainsi qu'une diminution de la 
densité du collagène et de l'élongation des noyaux cellulaires. Il y avait également une 
diminution significative de la contrainte à la rupture des TQRs aux jours 6 et 10 de 
privation de chargement par rapport aux tendons frais. 
De plus, nos résultats ont montré que le traitement PRP + IÉ, ajoutés à la faible charge 
statique, améliorait les propriétés mécaniques et histologiques des tendons modérément 
endommagés par rapport à d'autres traitements ou aux tendons non traités. La contrainte 
à la rupture des TQRs traités avec PRP + IÉ a été améliorée par rapport aux tendons privés 
de chargement au jour 10 (p = 0,01). Le traitement PRP + IÉ a également amélioré la 
densité des fibres, la forme du noyau et l’espace entre les fibres des TQRs par rapport aux 
TQRs privés de chargement au jour 10 (p <0,05). 
Conclusions: Le modèle simple ex vivo caractérisé dans cette étude est utile pour 
investiguer la progression de la TC et pour étudier l'efficacité des traitements potentiels 
pour arrêter ou inverser la progression de la pathologie. De plus, en utilisant ce modèle, 
nous avons introduit la thérapie combinée PRP et IÉ comme traitement potentiellement 
efficace pour la TC. 
xi 
Mots clés: tendinopathie, privation de charge mécanique, inhibiteur de métalloprotéinases 
de la matrice, plasma riche en plaquettes.
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Chapter 1. Introduction  
Tendons are those connective tissues which connect muscle to bone. They consist of two 
main parts: the extracellular matrix (ECM) and cells (tenocytes) which are, respectively, 
the inert and active components of tendons. These two components are in a close and 
bidirectional interaction. However, the mechanical behavior of the tendon is mostly 
devoted to the ECM, and cells are considered as responsible for tissue remodeling 42.  
ECM is mainly made up of water (~ 70%). The dry mass of ECM consists mostly of collagen, 
elastin, and proteoglycans. Collagen is the most abundant protein in ECM. It provides 
tendon strength against applied tensile load. Collagen parallel alignment along the tendon 
enables it to resist tensile load in this direction.  
Tenocytes: tenocytes, which are responsible for production of the ECM, have an elongated 
shape when observed in the tendon’s longitudinal orientation71. Whereas in cross-
sectional view, they appear as star-shaped64. Tenocytes are sparsely distributed between 
collagen fibers with their processes making an extensive network inside ECM114. They are 
highly responsive to their micro-environmental changes, such as mechanical loads or local 
stimuli28. For further details regarding tenocytes mechano-responsiveness see section 
2.1.2.  
Collagen in tendons adopts a hierarchical structure such as displayed in Figure 1.1. 
Collagen molecules unite into collagen fibrils, collagen fibers, subfascicles (primary 
bundles), fascicles (secondary bundles) and tertiary bundles53. Primary, secondary and 
tertiary fiber bundles are covered by a thin layer called endotenon and the whole tendon 
is surrounded by another thin layer called epitenon91. 
                                                        
 There have been some misunderstandings in literature regarding using “fiber” and “fibril”. In some texts, 
these two terms have been used interchangeably. 
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Figure 1.1 Schematic structure of a normal tendon49 
Tendon disorders are common health problems. For example, 1 of every 10 people and 1 
of every 2 runners experience Achilles tendon disorder before the age of 4598. The 
consequences of this medical problem include pain, disability, early retirement from sport 
and work, mental distress, health-care costs, etc.  
It should be noted that there is confusion in literature about terminology of tendon 
disorders. One term which has been used to address tendon problems is “tendinopathy”. 
Tendinopathy is a general term for tendon disorders with no assumption of underlying 
pathology. Traditionally, it was thought that underlying pathology of tendon disorders 
was due to inflammation2,27,83. This condition, i.e. tendon disorder accompanied by 
inflammation, is referred to as “tendinitis”. However, later, “non-inflammatory” or 
“degenerative” theory was considered to be the reason behind CT, or overuse injuries83. 
The term used to describe this condition i.e. degenerative condition of tendon without 
accompanying inflammation is “tendinosis”83,84. These three terms have often been used 
interchangeably which is inappropriate. We notify that in this research, the focus is on a 
tendinopathy model of chronic injury without inflammation.  
Some important features of CT in vivo based on literature include:  
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Clinical features: activity-related pain, tenderness, and impaired performance43. 
Histological features: hyper-cellularity, loss of  cytoplasm elongated shape,  rounder 
nuclei, neovascularization, disruption in collagen organization and orientation, decreasing 
collagen fibers size and increasing cross sectional area (CSA)43,55.  
Biochemical features: changes in gene expression and activity of biomolecules and 
proteins such as collagens and matrix metalloproteinases (MMPs), enzymes which 
degrade ECM (for further details, see Appendix). For example, it has been suggested that 
there is an increase in MMPs level in tendinopathic tendon5. However, these changes are 
often model-dependent. In other words, they depend on various factors such as species 
(human, rat, rabbit, etc), body parts (Achilles tendon, hamstring tendon, tail tendon, etc), 
and type of pathology (acute, overuse, stress deprivation, etc). 
Despite the prevalence of tendon problems, they are difficult to treat successfully84,86. 
Historically, treatment strategies were largely focusing on targeting inflammation such as 
rest, corticosteroid injection, or nonsteroidal anti-inflammatory drugs (NSIADs). 
However, since there is little or no inflammation in CT2,83, the results of these treatments 
on CT are usually unsatisfactory, and there is possibility of recurrence of symptoms43. 
Currently new promising treatments (see section 2.2) are being developed, but there is 
still little evidence to support their use. 
To find an optimal healing strategy, understanding the pathology behind tendinopathy is 
crucial. Using animal models is essential for in-depth studies on this subject. Therefore, in 
the first part of our literature review (Chapter 2), available models relating to CT are 
described.  
Models are not only beneficial for studying features and causes of CT, but they also enable 
studying potential treatments. Hence, available treatments for tendinopathy will be 
reviewed in the second part of our literature review. Thereafter, we will introduce the 
selected treatments to be studied in this research.  
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Two articles based on the findings of this research are presented in Chapters 3 and 4. In 
the first article (Chapter 3), a simple ex vivo model to create moderate CT has been 
characterized. The second article (Chapter 4) presents the results of applying two recent 
treatments (PRP, and MMPI) in combination and alone on this ex vivo tendinopathic model. 
Lastly, in Chapter 5, concluding remarks from the results of this project and suggestions 
for further work are outlined. 
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Chapter 2. Literature review 
2.1. Currently available ex vivo models for tendinopathy. 
There are numerous pathogenetic mechanisms behind tendinopathy. Moreover, tendons 
from different body parts, thus subjected to different mechanical and biological 
conditions, are affected by tendinopathy.  Therefore, it is unlikely that only one suitable 
model exists to represent all tendinopathy conditions.  
Tendinopathy models for the study of pathogenesis and the evaluation of potential 
treatments are developed either in vivo or ex vivo. In vivo models are those inducing 
tendinopathy in a live animal. Ex vivo models include those using a living tendon kept 
outside of the body under culture conditions.  
In vivo models are essential, because they enable us to have a more complete 
understanding of tendinopathy27. Ex vivo models are also critical, because they allow 
under specific, controlled conditions (e.g. defined media, defined loading protocol, …), the 
study of the pathological basis as well as of drug efficacy. Since in vivo models are costly 
and time-consuming, we decided to initially characterize an ex vivo tendinopathy model to 
verify our hypotheses. In the following sections, the current ex vivo chronic tendinopathy 
(CT) models will be explained. Finally, we conclude with the method we selected to create 
CT in this research. 
2.1.1. Ex vivo models of tendinopathy 
Ex vivo models of tendinopathy allow for great control over experimental conditions27, for 
example loading conditions or composition of culture media. Ex vivo models mainly use 
cyclic loading, and stress deprivation (SD) to induce tendinopathy in harvested tissues. In 
these models, there is no need to interact recurrently with animals, to make them exercise 
for example. Therefore, these models may be cheaper and less time consuming.  
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Cyclic loading 
This model has been developed to simulate the daily repetitive loading on live tendons. 
For example, Cousineau and Langelier22 used two loading conditions: i.e. 1.2% strain for 
underuse, and 1.8% strain for overuse. For both loading conditions, they have reported a 
decrease in the peak stress of the cyclically loaded rat tail tendons (RTTs) after 24 hours 
as well as changes in the ECM after 10 days, mainly for the underuse condition.  
In another study26, live avian flexor digitorum tendons were cyclically loaded to either 3 
(low), or 12 MPa (high), for either continuously 24 hours (short), or 2h/day for 12 days 
(long) at 1 Hz. The results revealed a decrease in maximum load at failure (N) of tendons 
loaded with the following regimens: low/long, high/short and high/long. Maximum stress 
at failure (MPa) of tendons which were loaded high/short or high/long also decreased 
significantly.  
Cellular deformation as a result of cyclic loading has been reported in a study on rat tail 
tendons7. The results of this study demonstrated that exposing tendons to 2%, 4% and 6% 
strain results in a deformation in cell nuclei.  
Cellular response to cyclic loading has also been the subject of some studies. For example,  
an increase in the level of PGE2 as a result of increasing loading duration of avian flexor 
digitorum tendons has been reported26. Moreover, a decrease in MMP-1 levels of cyclically 
loaded rat tail tendons has been demonstrated50. 
Stress deprivation 
Ex vivo SD also could cause tendon degeneration. This model has frequently been used to 
study tendinopathy. In the following paragraphs, two studies have been explained to 
introduce the general results. For further studies and results, please see Table 3.1 
(chapter 3). 
Arnockzky et al 5 developed a stress-deprived model by incubating live tendons without 
mechanical load for 7 days. This model produced a reduction in the intimate contact of cell 
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and its pericellular matrix; a reduction in collagen fibril packing; a reduction in ultimate 
stress, strain at ultimate stress, tensile modulus; and finally, an increased MMPs levels.  
In a study by Lavagnino et al 49, ex vivo stress deprivation resulted in a reduction in tensile 
properties without changes in collagens.  
For further details about the effect of stress deprivation on tendon properties ex vivo, 
please refer to Table 3.1 (chapter 3). 
2.1.2. Pathogenesis behind tendinopathy induced by stress deprivation 
and cyclic loading 
To address the reason of degradative effects of stress deprivation and cyclic loading on 
tissues, we should first consider that tendon is a mechanosensitive tissue which responds 
to loading in an adaptive manner45. Mechanical loading on tendons can be sensed by 
tendon cells via mechanotransduction mechanisms. Mechanotransduction mechanisms, 
by which mechanical stimulations are converted into biochemical signals, are mediated by 
cell deformation, nucleus deformation, cytoskeleton, stretch activated channels, and 
primary cilium100 (Figure 2.1).  According to Arnoczky et al 6, the character of cell response 
(catabolic vs. anabolic) to the perceived load depends on its threshold of sensitivity to 
external load. It has been demonstrated that the preset level of cell sensitivity to the 
applied load, which is called mechanostat set point of the cell, is regulated by cells through 
their ability to produce internal tension. This tension may help cells to maintain their 
homeostatic state of stress6. If the applied load is less than this set point, the response of 
cells will be catabolic, while if the load is higher than cell mechanostat set point, cell 
response will be anabolic.  
The degradative effects of stress deprivation, as a result of catabolic response of the cells, 
could be explained by this theory. Uchida et al 96 reported a simultaneous over-expression 
of cytokines such as IL-1b and TNF-a following stress deprivation. These signaling 
molecules are well-known to stimulate MMPs-1 and -3 in fibroblasts. They addressed 
these ECM-degradative enzymes as the reason of destructive effects of stress deprivation. 
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However, they did not explain the reason of the catabolic cell response, which seems to be 
related to mechanostat set point of the cells.  
In cyclic loading, beside cell response, mechanical degradation of ECM should also be taken 
into account. Since tendons have a viscoelastic behavior, the factors which mediate 
mechanical degradation include: the amount, the frequency and the rate of applied load, 
and rest periods between loading episodes. Mechanical degradation would lead to 
tendinopathy if the anabolic response is insufficient to repair tissue damage. This would 
lead to the accumulation of micro tears in collagen fibers. The partial damages of collagens 
unable them to properly transfer the external load to cells; as a result, tendon cells 
undergo understimulation. It means that their perceived load is less than their 
mechanostat set point.  Therefore, their response would be catabolic, and they produce 
degeneration which may eventually lead to tendinopathy4. Although the etiology is likely 
more complicated than this, accumulation of microdamages as a result of fatigue loading 
has been considered a significant reason for overuse injuries26. 
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Figure 2.1 Tissue mechanobiological response including cellular response and extracellular 
matrix mechanical damage. Note the mechanotransduction mechanisms by which cell 
senses the mechanical loading. 
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2.1.3. The preferred CT model 
Among all ex vivo tendinopathy models, we chose SD to characterize CT in our laboratory. 
We use SD because it could be achieved by using a simple experimental setup. Therefore, 
there is no need to use the bioreactor which is not very stable and also has the limitation 
of number of samples per experiment (4 tendons). Moreover, preparing the samples in 
this model is less expensive in terms of cost and length of experiment. This is in 
concordance to the objectives of this research study: because we need to control multiple 
factors in each experiment, this model allows for having enough samples simultaneously. 
Moreover, since these samples could all be extracted from the same animal, the risk of 
inter-animal variability is also reduced, as well as the number of sacrificed animals. 
2.2. Current healing strategies available to treat tendinopathy 
Despite the prevalence of tendinopathy, the available healing strategies are not completely 
satisfactory43. Traditional treatments focused on anti-inflammatory drugs such as 
corticosteroid injections and non-steroidal anti-inflammatory drugs (NSAID) drugs. 
However, it may not be the most appropriate target2, because it has been suggested that 
there is little or no inflammation in CT2. Even in tendinitis, there is debate on whether 
blocking the inflammatory response will be helpful or not84.                                                                                                                            
Currently, several treatments, (including eccentric exercises, pharmacological treatments, 
etc) have been introduced to heal tendinopathy. However, there is little high-quality 
studies to confirm their clinical use21,72,90. A summary of current non-surgical 
tendinopathy treatments is demonstrated in Table 2.1.  
 Table 2.1 The rational and efficacy of available tendinopathy treatments2,43,84,86  
Treatments Rationale or Function Efficacy and State-Of-The-Art 
Non-pharmacological treatments 
Ice43,86 Reduction of acute inflammation, because of the 
reduction in blood flow and metabolism rate 
Good efficacy on short-term pain relief 
No efficacy on long-term pain relief 
Little research has been done on it 
Therapeutic 
ultrasound2,43,84,86 
Thermal effects on tissue, cell activity stimulation 
and blood flow increase 
Little or good efficacy on short-term pain 
reduction 
No efficacy on long-term pain reduction 
Controversy in the literature and little 
evidence to support its use 
Laser therapy2,84,86 Possible analgesic effects and some unknown 
effects on cell activity 
 
Little or good efficacy on short-term pain 
reduction 
No efficacy on long-term pain reduction 
Contradictory results 
   
Friction massage2,43,84 Cell activity stimulation and blood flow increase Little or good efficacy on short-term pain 
reduction 
No efficacy on long-term pain reduction 
Controversy in the literature and little 
evidence to support its use 
Soft tissue 
mobilization2,84 
Cell activity stimulation and blood flow increase Little or good efficacy on short-term pain 
reduction 
No efficacy on long-term pain reduction 
Controversy in the literature and little 
evidence to support its use 
Orthotic devices43,84,86 Correcting a static disorder, removal of 
precipitating factors and prevention of reinjury 
Good efficacy on short-term pain relief 
No efficacy on long-term pain relief 
Little evidence to support their 
effectiveness 
 Eccentric exercise2,43,84,86 Promote regeneration of normal tissue structure, 
probably through an effect on cell activity and 
matrix remodeling 
Good efficacy on short-term pain relief 
and long-term pain relief 
It is currently considered to be the most 
efficient treatment for tendinopathy, 
although some studies are contradictory 
Extracorporeal Shock 
Wave Therapy 
(ESWT)2,43,84,86 
Promote tissue healing by stimulation of cell 
activity, and neovascularization, induction of 
growth factors (TGF-β1 and IGF-1), increased 
tenocyte proliferation and collagen synthesis 
Very good efficacy on short-term pain 
relief and long-term pain relief 
Some evidence to support its use in 
calcific tendinopathies of the rotator cuff 
No clear evidence, or little evidence 
(controversial information) supporting 
its use in the treatment of chronic tennis 
elbow, medial epicondylitis, Achilles and 
patellar tendinopathies 
Pharmacological treatments 
Nonsteroidal Anti-
inflammatory Drugs 
(NSAIDs)2,43,84,86 
Reduction of inflammation through inhibition of 
inflammatory factors synthesis 
Good efficacy on acute pain 
No efficacy on long-term pain relief 
Researches in acute tendon injury model 
showed NSAID administration did not 
 prevent collagen degradation or loss of 
tensile force in tendons 
Its use is still controversy regarding the 
lack of existence of inflammation in 
degeneration 
Corticosteroid 
injections2,43,84,86 
Reduction of inflammation by inhibition of the 
synthesis of cytokine genes and proinflammatory 
factors 
Good efficacy on short-term pain relief 
Little or no efficacy on long-term pain 
relief 
Mixed results 
Corticosteroids can cause spontaneous 
tendon rupture 
No evidence to prove its efficiency for 
chronic tendinopathy 
Heparin84,86 Effect on tendon blood flow; possibly results in 
improved healing 
In a review in 2006, it was mentioned 
that it has some constructive effects, but 
more recent animal study found heparin 
had a degenerative effect 
 It has not been mentioned in the more 
recent reviews (2008, and 2011), 
therefore may be it is no more an option 
Dextrose84 Possibility of releasing growth factors (GFs) and 
therefore local tissue proliferation 
Since there is no control data nothing can 
be said 
It has not been mentioned in the 
reviewed literature as a potential 
treatment since the 2006 review article 
MMP inhibitors43,84 Promoting healing by inhibiting the enzymes which 
break down tendons, i.e. MMPs.  
Because it has been established that using 
conventional treatments with the effect of 
inflammatory suppression 
May not fully inhibit MMP-based tendon 
degradation 
Very good efficacy on short-term pain 
relief and long-term pain relief 
In clinical trials, aprotinin was used as a 
broad-spectrum MMP inhibitor 
Good clinical improvement mild-Achilles 
tendinopathy patients were treated more 
successfully than patellar 
Aprotinin may cause anaphylaxis, more 
studies are needed 
 Injections of blood or 
PRP2,43,84,86 
Contains growth factors (e.g. transforming growth 
factor β and platelet-derived growth factor) that 
promote matrix synthesis and tissue repair 
Little or no efficacy on short-term pain 
relief 
Very good efficacy on long-term pain 
relief 
There have been only a few clinical 
studies in recent years with good results, 
but in vitro studies have promising 
results. 
Other controlled studies are needed 
Sclerosant 
injections2,43,84,86 
Blocks tendon blood flow (targeting 
neovascularization and associated pain generating 
nerve in-growth) 
Very good efficacy on short-term pain 
relief and long-term pain relief 
In clinical trials polidocanol was used as 
sclerosant agent 
Some clinical studies report goodshort- 
and/or long-term result with an increase 
in strength and a decrease in pain 
Other studies needed to evaluate its 
safety, efficacy, and combination with 
other drugs 
 Topical glyceryl 
trinitrate2,43,84,86 
Enhances collagen synthesis Very good efficacy on short-term pain 
relief 
Excellent efficacy on long-term pain relief 
Few clinical trials, reported benefit on 
patient-determined pain, function, and 
loss of symptoms on Achilles 
tendinopathy, chronic supraspinatus 
tendinopathy and lateral elbow 
tendinopathy 
Polysulphated 
glycosaminoglycan84 
Inhibition of inflammation, possibly also acting to 
inhibit metalloproteinase enzyme activity 
A number of studies suggesting that 
injection of glycosaminoglycan 
polysulphate may lead to an 
improvement in disease of the human 
Achilles and equine superficial digital 
flexor tendon. 
It has not been mentioned in the recent 
reviews (2008, and 2011), therefore may 
be it is no more an option 
Botulinum toxin A (BTA) 
injections43 
Paralysis caused by BTA involves a reduction in 
tensile stress on the enthesis 
Very good efficacy on short-term pain 
relief 
 Good efficacy on long-term pain relief 
Few articles from last years have 
considered the possibility of making 
botulinum toxin injections (BTA) to treat 
epicondylitis 
Stem-cell or gene 
therapy2,43,84,86 
Stem cells will be isolated and located in the area of 
injury or degeneration. Then with local signaling or 
some exogenous factors, they will be stimulated to 
differentiate to particular cells 
Unknown efficacy on pain relief 
There are promising in vitro results for 
using stem-cell or gene in treatment of 
tendinopathy.  
Animal studies suggest that gene therapy 
may also improve the capacity of the 
injured tendon to heal 
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Among all potential treatments, we selected platelet-rich plasma (PRP) and matrix 
metalloproteinase inhibitors (MMPIs) to apply in our laboratory. To explain this choice, 
we refer to the following model for tendon mechanobiological response (TMR) (Figure 
2.1) as:  TMR = Repair – (Mechanical degradation + Enzymatic degradation)22.                     
This model highlights that the combination of these treatments might be beneficial to 
simultaneously promote regeneration and inhibit enzymatic degeneration. First, PRP 
would enhance tendon repair through the release of a variety of autologous growth factors 
(GFs) playing a key role in tendon repair mechanisms68. Second, MMPIs would inhibit 
proteolytic degradation of connective tissues mediated by MMPs. However, in our 
knowledge the combination of these two treatments has not been studied so far.  
In the following section these two healing strategies are explained with more details. 
2.3. MMPIs and PRPs: The selected healing strategies to apply 
in ex vivo created tendinopathy models 
2.3.1. MMPIs: general information 
Natural and synthetic MMPIs 
MMPIs are enzymes inhibiting the activity and/or expression of MMPs. MMPs are ECM 
proteolytic enzymes mediating ECM turnover. ECM equilibrium is mediated by, inter alia, 
a balance between the levels of MMPs and their natural inhibitors, called tissue inhibitors 
of matrix metalloproteinases (TIMPs). 
Dysregulation of the balance between the levels of MMPs and TIMPs interrupts ECM 
equilibrium. High levels of MMPs could cause tendon degeneration and rupture. 
Therefore, inhibiting MMPs has been considered as a therapy option for tendinopathy5,73. 
MMPIs could be endogenous such as TIMPs, or exogenous such as synthetic MMPIs. TIMPs 
are divided into four categories: TIMP1, TIMP2, TIMP3, TIMP4. They inhibit all MMPs, 
however, the ability of some of TIMPs to inhibit some specific MMPs needs to be elucidated 
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in future studies. TIMPs function is not limited to inhibition of MMPs. They also play roles 
in regulation of angiogenesis and cellular proliferation78.  
Although TIMPs have stronger inhibitory effect than synthetic MMPIs, to our knowledge, 
they have never been used as therapeutic agents to promote tendon healing ex vivo or in 
vivo. Before further using them as treatment in diverse pathologies, it has been suggested 
to deepen our  understanding of TIMPs’ activities  (other than inhibitory ones), since they 
may cause some unwanted side effects10. Moreover, their broad-spectrum inhibitory effect 
makes them undesirable in studies with specific MMPs in target. However, TIMPs could be 
modified in order to retain their inhibitory effect without their other unwanted biological 
activities. In this way, they may be applied for therapeutic benefits in future10. 
It should be noted that TIMPs have been used as therapeutic agent in some studies of other 
disease. For instance, Li et al have shown promising results of using recombinant TIMP-2 
in cancer treatment52.   
Synthetic MMPIs have been used as therapeutic agents in MMP-mediated disease. There 
are several studies with using synthetic MMPIs to promote tendon healing ex vivo and in 
vivo. Some of them will be presented in the following sections. 
The effect of MMPIs on tendons in ex vivo and in vivo animal studies 
Excessive action of MMPs may lead to degeneration and weakening of ECM. Therefore, in 
this condition, drugs that can decrease the MMPs activity, and therefore ECM 
degeneration, may play a significant role in promoting tendon healing5.  In some ex vivo 
and in vivo studies, MMPIs were used to affect MMP activity and prevent or reverse the 
process of MMP-mediated ECM degeneration in tendons. Table 2.2 summarizes the result 
of MMPI application on tendons in some studies ex vivo, and in vivo. It should be noted that 
most of the studies were conducted on surgically-induced tendinopathy, i.e. partially or 
completely sectioning the tendon using a scalpel and then stitching damaged tendons or 
leaving them unsutured, models which do not reflect CT.
 Table 2.2 Data extracted from MMPI studies. N/A stands for data not available. 
Reference Model Experiment Results 
Bedi et al, 13 
2002 
 In vivo 
 Rat, male, 
250-300g 
 Rotator cuff 
 Surgically 
induced 
damage 
Treatment 
 Doxycycline 
 @ preoperative day (D-1), or @ 5 
and 14 days postoperative (D+5 and 
D+14) until the time of sacrifice 
Analysis:  
 Postoperative day (POD) #5, #8, 
#14, #28 
Biomechanical 
 D-1: Increased load to failure at 2 wks 
compared to control, (and no difference at 
day 8) 
 D+5: Increased load to failure at 2 wks 
compared to control, (and no difference at 
day 8) 
 D+14: No difference 
Histological 
 D-1: Improved collagen organization at 
POD#5, #8, #14; 
 D+5: Improved collagen organization at 
POD#14; 
 D+14:No difference 
Biochemical 
 D-1: Reduced MMP13 activity at POD#8 
compared to control, 
 Arnoczky et 
al, 5 2007 
 Ex vivo 
 Rat, adult 
 Tail tendon 
 Healthy  
Treatment 
 Doxycycline or Ilomastat 
 @ day 0 
Analysis:  
 7 days after first MMPIs application 
Biomechanical 
 Improvement in ultimate stress, tensile 
modulus, and strain at ultimate stress with 
either of MMPIs compared to 7-day SD 
Histological 
 Limited the alteration in the pericellular 
matrix shape, and loss of cell-matrix contact 
with either of MMPIs; 
Biochemical 
 Reduction in MMP13 activity with either of 
MMPIs, 
 No effect on MMP13 protein synthesis with 
either of MMPIs 
Demirag et al, 
25 2005 
 
 In vivo 
 Rabbit, 3.5-4 
kg 
 Anterior 
cruciate 
ligament 
 Surgically 
induced 
damage 
Treatment 
 A-2-macroglobulin 
 @ day 0 and 1 after surgery 
Analysis:  
 2 and 5 weeks post-surgery 
Biomechanical 
 Greater load to failure at both 2 and 5 
weeks  
Histological 
 Dense, more mature, perpendicular 
collagen fibers 
Biochemical 
 Decreased MMP-8 activity 
 Kessler et al, 
44 2014 
 
 In vivo 
 Rat, male, 
300-400 g 
 Achilles 
 Surgically 
induced 
damage 
Treatment 
 Doxycycline 
 Starting @ preoperative day, 
continued up to 4 weeks 
Analysis: 
 2 or 4 weeks for histology; 3 weeks 
for biomechanical properties 
 
Biomechanical 
 Enhanced biomechanical properties 
Histological 
 Improved collagen fiber organization 
Biochemical 
 Reduced MMP activity 
Nquyen et al, 
70 2017 
 
 In vivo 
 Rat, male, 2-3 
months old 
 Achilles 
 Surgically 
induced 
damage 
Treatment 
 Doxycycline  
 Daily administration of MMPI one 
day after injury 
Analysis:  
 1.5, 3, 6, 9 weeks after injury 
Biomechanical 
 Accelerated recovery in biomechanical 
properties (i.e., greater equilibrium 
modulus, higher dynamic modulus and 
lower creep strain) 
Histological 
 Improved tissue organization, fiber 
alignment, and decreased fiber dispersion 
Biochemical 
 Decreased MMP3 expression at 9 wks 
Bedi et al, 14 
2010 
 In vivo 
 Rat, male, 
250-300 g 
Treatment 
 A-2-macroglobulin 
 @ day 0 
Biomechanical 
 No change in load to failure, or stiffness  
Histological 
   Rotator cuff 
 Surgically 
induced 
damage 
Analysis:  
 2 or 4 weeks after surgery 
 Greater collagen organization at 4 wks; but 
not at 2 wks 
 Reduction in collagen degradation at both 2, 
and 4 wks 
Biochemical 
 None 
Orner et al, 74 
2016 
 
 In vivo 
 Mouse, 
female, 8-10 
weeks 
 Flexor tendon 
 Surgically 
induced 
damage 
Treatment 
 MMP 9 inhibitor 
 Daily administration of MMPI 
starting @ the day of surgery, until 
day 8 post surgery 
Analysis:  
 7-35 days post surgery 
Biomechanical 
 No difference in biomechanical properties 
(stiffness, and max load at failure)  
Histological 
 No alteration in tendon morphology  
Biochemical 
 Decreased MMP9 activity 
Pasternal et 
al, 79 2006 
 
 In vivo 
 Rat 
 Achilles 
 Surgically 
induced 
damage 
Treatment 
 Doxycucline 
 Starting @ 1 day before surgery 
until the time of sacrifice 
Analysis:  
 5, 8, and 14 days after surgery 
Biomechanical 
 Decreased force at failure, and energy 
uptake   
Histological 
 None 
Biochemical 
 None 
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It can be concluded from Table 2.2 that using broad-spectrum MMPIs (BI; e.g., doxycycline 
and alpha-2-macroglobulin) in surgically induced tendinopathy models results in greater 
collagen organization14,25,44,70, as well as a reduction in collagen degradation14,70, limited 
MMP activity25,44,70, and increased mechanical strength25,44,70.  
The effect of MMPIs on tendons in clinical trials 
Beside laboratories, MMPIs have also been used in clinical trials to improve tendon 
healing. Aprotinin is a broad-spectrum MMPI which was initially used for limiting blood 
loss during surgery and promoting soft tissue healing after surgery73. Years later, it was 
introduced as therapy option for chronic tendinopathy. In clinic, aprotinin has been used 
for treating chronic patellar and Achilles tendinopathies. In one randomized control trial, 
aprotinin presented superior results than both corticosteroid and saline injections in 
chronic patellar tendinopathy,  12 months after injection17. The results are mixed about 
the effect of aprotinin on Achilles tendinopathy. Some uncontrolled or poorly controlled 
studies reported high rates of success in management of chronic Achilles tendinopathy 
with aprotinin9,19. In a study by Brown et al17 on chronic tendinopathy, there was no 
significant difference but a trend toward better results by aprotinin than placebo. Another 
clinical outcome73, demonstrated that in treating chronic tendinopathy, using aprotinin 
led to more successful results for treating mid-Achilles tendons than patellar tendons. 
Although excess activity of MMPs may lead to degeneration and weakening of ECM, normal 
actions of MMPs are needed for ECM remodeling and repair. It should be noted that 
applying MMPIs to promote healing in some cases may adversely affect the healing 
process. In this regard, Pasternak et al79 conducted a test evaluating the effect of broad-
spectrum MMPI, doxycycline, in the prevention or healing of the acute injury of Achilles 
tendon in rats in vivo. Their results demonstrated negative influence of doxycycline on 
early stages of tendon healing as measured in tension test by force and energy uptake at 
failure. These results could be explained by the fact that there was tendon regeneration at 
the site of injury consisting of a loose collagenous network including mostly proteoglycan 
and collagen III. MMPs are fundamental to remove this newly formed loose callus to be 
replaced by more densely organized collagens, mostly collagen I. In fact, this removal is 
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needed for remodeling and consequently building stronger tissue. The negative result 
from this study and positive result from literature reviewed in the previous section imply 
that the effect of MMPIs on tendon healing is strongly case-dependent.  
Therefore, before applying MMPIs to prevent or heal tendinopathy, this dual activity of 
MMPs should be taken into account. That is, while in one pathologic model, specific MMP 
might play a negative role, in another pathologic model, the role of that specific MMP might 
be positive on tissue quality. In conclusion, the alteration in the presence and activity of 
MMPs should be studied in each pathologic model, to be able to target MMPs which are 
destructive to tendon health. 
Narrow or broad-spectrum MMPIs  
There are some evidence that broad-spectrum MMP inhibition impairs tendon healing, 
since MMPs play fundamental role in remodeling and healing46,54,75,79. Therefore, more 
selective inhibition might lead to positive effects. In fact, it would be beneficial to target 
specific MMPs which are detrimental to tendon healing, without affecting MMPs which act 
during tendon healing.  This could be achieved by applying narrow-spectrum MMPIs (NI) 
instead of broad-spectrum MMPIs (BI).  
Obviously, choosing appropriate NI, requires identifying MMPs deleterious to tendon 
healing. Based on the information in the literature regarding destructive MMPs present in 
tendinopathic rat tendons, MMPs 9 and 13 have first been selected as target MMPs to 
inhibit by our group. It should be noted that RT-PCR analysis has been performed by our 
group on 6-day stress-deprived RTTs and an increase in MMP9 and MMP13 has been 
reported (Figure 2.2). However, for our ex vivo experiment, we focused on MMP13. It is 
because MMP13 in rats is equivalent to MMP1 (interstitial collagenase) in human and 
because its expression has been reported to be increased in pathological human tendons5. 
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2.3.2. PRP: general information 
PRP therapy is one new alternative in tendon healing. PRP is a blood product obtained 
from whole blood that contains a high concentration of platelets. The beneficial effect of 
PRP is probably related to providing an environment full of bioactive molecules and GFs 
appropriate for tissue regeneration. This environment enables cell migration and 
proliferation, angiogenesis, and matrix deposition in tendon healing11. 
Clinical use of PRP in tendon healing has been expanded, despite the lack of enough 
randomized control trials with large scales11. However, in order to clinically use PRP safely 
and more efficiently, more high-quality in vivo and ex vivo studies should be conducted. 
In the following section, the PRP biological activity will be explained with more details. 
Then the current state-of-the-art in using PRP in tendon healing in ex vivo and in vivo 
animal studies, and in clinical trials will be introduced. 
 
Figure 2.2 Increased MMP9 and MMP13 in 6-day SD tendon samples by PCR analysis. 
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PRP biological activity 
The beneficial effects of PRP at molecular levels is attributed to the high concentrate 
content of GFs and proteins of cytokine and chemokine families which are secreted from 
activated platelets105. Platelets can be activated, i.e. aggregated, endogenously during 
injury to the vessel wall, or exogenously by being exposed to bovine thrombin, calcium, or 
collagen type 1105. Releasing GFs and proteins to the site of injury improves tissue 
regeneration. Some GFs identified in PRP include platelet-derived growth factor (PDGF), 
transforming growth factor (TGF) , basic fibroblast growth factor (bFGF), vascular 
endothelial growth factor (VEGF), insulin-like growth factor (IGF), hepatocyte growth 
factor (HGF), and epidermal growth factor (EGF). Table 2.3 demonstrate the roles of these 
growth factors produced by activated platelets94.  
  
The effect of PRP on tendons in ex vivo and in vivo animal studies 
PRP enhances tendon healing by promoting tissue regeneration. The rationale behind 
using PRP is to have concentrated platelets at the site of tendon injury. These activated, 
more concentrated platelets release GFs which benefit tissue healing. PRP affects tissue in 
several aspects: 
Table 2.3 GFs released by activated platelets86. 
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GFs: One of these aspects is increasing GFs such as PDGF and TGF, and VEGF. Increasing 
PDGF and TGF enhance recruitment of inflammatory cells, which consequently release 
additional growth factors11,68,89. Moreover, VEGF which plays a key role in signaling 
angiogenesis pathway is affected by PRPs. In fact, PRP enhances vascularisation, and 
consequently tendon healing of surgically induced tendinopathies, in vivo by increasing 
VEGF expression11. 
Tenocyte proliferation: In vitro application of PRP on healthy tendons significantly 
increases tenocyte proliferation3,68. However, the positive or negative clinically result of 
tenocyte proliferation has not yet been investigated11.  
Collagen expression: PRP affects collagen expression by increasing total collagen 
expression. De Mos et al.68 reported a decrease in the gene expression of both collagen I 
and collagen III of healthy tendons treated with PRP, while increasing the overall collagen 
production. This increase in total collagen production is probably attributable to cell 
proliferation. However, they reported no change in the ratio of Collagen I / Collagen III. In 
another study, there was a significant increase in mRNA expression of collagen I, collagen 
III, and ratio of collagen I / collagen III89. More studies are needed to clarify the effect of 
PRP on collagen I and collagen III expression. 
Rate of repair: Some in vivo animal studies showed that PRP-treated tendons, with 
surgically induced tendinopathy, healed faster than control tendons56–59. In fact, they 
reported enhanced vascularisation in the PRP-treated group leading to accelerated 
healing process. 
Quality of repaired tendon 
Histology: Using PRP enhances the histological quality of repaired tendon. More mature, 
dense and better organized collagen fibers, with more oriented tenocytes have been 
reported in some in vivo animal studies  surgically induced tendinopathy16,56–59. 
Strength: PRP enhances the mechanical properties of regenerated tendons which were 
exposed to surgically induced tendinopathy. Lyras et al, reported an increase in force at 
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failure, ultimate stress, and stiffness of the PRP-treated group compared with control 
group58. In another study, the repaired tendon in PRP-group featured higher strength at 
failure and elastic modulus16. 
MMP expression: PRP alters gene expression of matrix metalloproteinases (MMPs). In 
human tenocyte culture, PRP increases MMP1 and MMP3 slightly. However, MMP13 
expression was not affected by PRP68. In another ex vivo study on equine flexor digitorum 
superficialis tendon, no change was reported in MMP3 and MMP13 gene expression in 
response to PRP treatment89. It should be noted that with the current knowledge, it is 
difficult to state whether increasing MMP1 and MMP3 expression is beneficial for tendon 
repair68. 
Altogether, based on the literature, there are some evidences of the beneficial effect of 
using PRP to heal traumatic tendon injury. However more high-quality studies are needed 
to assess biological activity of PRP and its effect on tissue. Moreover, whether these results 
are applicable to CT is to be elucidated. In the next section, the results of using PRP to heal 
CT is presented. 
The effect of PRP on tendons in clinical trials 
Using autologous blood product such as PRP seems a natural and safe way to improve 
healing. Clinical trials have shown promising results, however more high-quality clinical 
trials with long-term follow-up are needed to prove the efficacy of PRP in tendon disorders 
healing94. The efficacy of PRP in healing of tendinopathies such as lateral elbow 
tendinopathy, rotator cuff repair, Achilles tendon repair, and patellar tendinopathy has 
been investigated in clinical trials. The results are summarized bellow.  
Elbow tendinopathy: In a retrospective study by Mautner et al63, patients with different 
chronic tendinopathies including elbow tendinopathy, received PRP injection. Ninety 
three percent of patients with elbow tendinopathy reported moderate improvement to 
complete resolution of symptoms. In a randomized control trial81, application of PRP 
versus corticosteroid resulted in a significant increase in functionality and reduction of 
pain of tendons with CT. In another control study, patients with chronic elbow tendinosis 
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receiving PRP demonstrated improvement in their visual analog pain scores to 60%, 81% 
and 93% at 8 weeks, 6 months, and 25.6 month post-treatment, respectively66. A review 
study mentions that currently there is more evidence for the efficiency of PRP in treating 
lateral elbow tendinopathy than other anatomical areas94.  
Rotator cuff tendinopathy: In Mautner et al study63, 81% of patients with rotator cuff CT 
reported moderate improvement to complete resolution of symptoms at least 6 month 
after receiving PRP injection. There are also some studies investigating the effect of PRP 
on rotator cuff acute injury. 
Achilles tendinopathy: In Mautner et al study63, 100% of patients with chronic Achilles 
tendinopathy reported moderate improvement to complete resolution of symptoms at 
least 6 month after receiving PRP injection. However, in a randomized control trial study, 
PRP injection in patients with chronic midportion Achilles tendinopathy combined with 
an eccentric training program revealed no benefit in clinical and structural properties of 
tendon over placebo injection at 1 year follow-up41. There is a need for randomized control 
trials to clarify the effect of PRP therapy on Achilles tendon disorder. 
Patellar tendinopathy: In Mautner et al study63, 59% of patients with chronic patellar 
tendinopathy reported moderate improvement to complete resolution of symptoms at 
least 6 month after receiving PRP injection. In a small non-control study, 20 patients with 
chronic patellar tendinopathy received PRP injection. There was encouraging results with 
regard to reducing pain and regaining functionality at 6-month follow-up47. Large-scale 
controlled studies with longer follow-up are needed on this subject. 
Altogether, conducting further preclinical models are essential to define tendinopathy 
features and verify the efficacy of treatments. Moreover, it seems that part of treatment 
strategies should focus on combination of treatments in order to benefit from their 
strengths and control their weakness.  
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2.4. Problematic  
Tendon is a soft tissue which transmits the force generated by muscle to bone. Tendon 
injury causes marked morbidity and may have a significant impact on many aspects of the 
patients’ life including work, sport, and even daily needs. Unfortunately, tendon injuries 
are highly prevalent. By increasing the number of people participating in physical and 
recreational activities every year, more people will likely be involved with soft tissue 
disorders resulting in increasing health care cost, and patient morbidity40. Even people 
with no intensive activities are prone to tendinopathy. For example, in a study of 58 
patients with Achilles tendinopathy, 31% of whom had no vigorous physical activity84. 
Although tendon disorder is a common and growing problem, the ideal treatment is still 
unclear. Traditional treatments may not be the most effective option because they have a 
high emphasis on anti-inflammatory strategies, while in most cases the pathology 
underlying tendinopathy is degeneration and not inflammation. There are numerous 
newer treatments currently available to cure tendinopathy. However, many of these 
treatments have a poor or no evidence base84.  
Defining the aetiology and pathogenesis of tendinopathy may lead to more rational and 
efficient treatments. The aetiology of tendinopathy seems to be multifactorial, and the 
pathogenesis of tendinopathy is still unclear101. While there has been some progress in 
understanding tendinopathy, the condition remains poorly understood27,111. Moreover, 
studying the pathogenesis of tendinopathy in human is difficult, because the available 
tendinopathy samples come from individuals with advanced pathology27. Therefore, there 
is a need to develop animal tendinopathy models, ex vivo or in vivo, to better understand 
tendinopathy and develop treatments for this disorder.  While animal models have been 
frequently used to study tendinopathy, most of these studies have investigated either early 
tendinopathy or advanced tendinopathy, and the transient mid-term tendinopathy has 
been given less attention. We refer to this transient stage between early and advanced 
tendinopathy, as moderate tendinopathy. Moderate-stage tendinopathy becomes even 
more important when investigating the potential efficacy of treatments. This is because 
early-stage human tendinopathy is often asymptomatic48,65 and patients often do not seek 
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medical attention. On the other hand, advanced tendinopathy usually requires invasive 
surgery for treatment51. Therefore, moderate tendinopathy would be a better time for 
studies that aim to estimate the effectiveness of new pharmacotherapies.  
To the best of our knowledge, there is no clear clinical translation of different levels of 
tendinopathy. However, we suggest moderate hiatopathological features in the 
tendinopathic tendons could probably represent a moderate tendinopathy in clinics. That 
is, for example, hypercellularity; several partial collagen tears without a complete rupture; 
changes in the intensity of imaging signals which are typical of well-aligned collagen fibers, 
at ultrasonography (US) or magnetic resonance imaging (MRI).  
This research study aims at creating moderate tendinopathy model ex vivo for the study 
the pathogenesis of tendinopathy and to investigate the efficacy of promising and new 
treatments, consisting of selective MMPIs and PRP, applied either alone or in combination. 
2.5. Research hypotheses  
The hypotheses of this research study are:  
1. A rat tail tendon develops moderate tendinopathy after 4 days of stress deprivation 
in culture conditions ex vivo; 
2. The combination of NI and PRP is more efficient for the treatment of moderate 
tendinopathy ex vivo than each modality alone. 
2.6. Objectives 
The objectives of this project are: 
1. Characterizing moderate tendinopathy model ex vivo. 
a. Characterizing rat tail tendinopathy model via stress deprivation ex vivo. 
b. Verifying the validity of the model by comparing the achieved results in 
terms of histological, biochemical, and mechanical features with control 
tendons and tendinopathy features documented in literature. 
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2. Studying the effect of two treatment modalities (MMP inhibitor and PRP injection), 
in combination and alone, on the ex vivo tendinopathy model. 
a. Applying MMP inhibitor and PRP, in combination and alone, on created 
model of moderate tendinopathy ex vivo. 
b. Evaluating the efficacy of treatments by comparing the changes in 
histological, biochemical, and mechanical features of treated tendinopathic 
tissues, untreated tendinopathic tissues, and fresh healthy tendons.   
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Chapter 3. Characterization of moderate 
tendinopathy in ex vivo stress-deprived rat tail 
tendons 
3.1. ABSTRACT  
Stress deprivation (SD) has frequently been used as a model to study tendinopathy. Most 
of these studies have investigated either short-term (early tendinopathy) or long-term SD 
(advanced tendinopathy), while the transient mid-term SD has been given less attention. 
Therefore, the main objective of this study was to characterize mid-term SD. To this end, 
live, healthy rat tail tendons (RTTs) were harvested and cultured without mechanical 
stress and then were divided into five groups based on their culture time (fresh, 2-day SD, 
4-day SD, 6-day SD, and 10-day SD). For each group, the tendons were subjected to traction 
testing and histopathological, biochemical, and viability assays. Our results showed that 4 
days of SD resulted in moderate pathological changes in RTTs. These changes included 
increases in the space between fibers, cell density, and collagen tortuosity as well as a 
decrease in collagen density and elongation of cell nuclei. No changes in the stress at 
failure of tendons were observed at this time point. This simple ex vivo model is expected 
to be useful for studying the progression of tendinopathy as well as for testing potential 
mechanobiological or pharmacological strategies to stop or reverse the progression of the 
pathology. 
Keywords: animal, stress deprivation, tendon, mechanical properties, biochemical 
properties, histology, degradation, MMP, collagen 
3.2. INTRODUCTION  
Tendinopathy is a frequent health problem that accounts for over 65% of work-related 
musculoskeletal disorders31. It is important not only to study and understand 
tendinopathy because of its prevalence but also to find an optimal treatment for the 
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disease. Many treatment modalities have been proposed for tendinopathy (e.g., 
nonsteroidal anti-inflammatory drugs, stem cell or gene therapy, eccentric exercises, laser 
therapy). However, there is very little support of the efficacy of these treatments106. In 
vitro, ex vivo and in vivo models of tendinopathy are part of a multiscale approach to 
understand and develop treatments for tendon disorders15,48. Stress deprivation (SD) of 
tendon tissues has been frequently used to develop such models6,30,34. SD can be 
categorized as short term or long term based on the investigation time points and the 
obtained results. For example, studies using short-term ex vivo SD models at 24 h, 48 h, 
and 72 h6,30,34 observed increases in apoptosis, cell roundness, and MMP 13 gene/protein 
expression as well as a decrease in fiber density. In addition to these early changes, long-
term studies at 6 days, 12 days102, 1 week, 2 weeks, and 8 weeks1,5,37,49 observed increases 
in collagen fiber waviness and disorientation, a decrease in mechanical properties and an 
increase followed by a decrease in cell density. Table 3.1 summarizes the results from 
previous ex vivo studies on stress-deprived tendons. These studies allowed 
characterization of short-term (early) and long-term (advanced) tendinopathy models. 
However, there is still a need to study different time points within this interval to better 
understand the transition of the tissue condition during the progression from early to 
advanced tendinopathy. This transition state shall be referred to as moderate 
tendinopathy. 
In addition to studying early and advanced tendinopathy, studying moderate 
tendinopathy is crucial to understand all stages of damage that the tendons experience 
during lesion development. Moderate-stage tendinopathy becomes even more important 
when investigating the potential efficacy of treatments because early-stage human 
tendinopathy is often asymptomatic48,65 and patients often do not seek medical attention. 
Advanced tendinopathy, however, usually requires invasive surgery for treatment51. 
Therefore, moderate tendinopathy would be a better time for studies that are designed to 
estimate the effectiveness of new pharmacotherapies. 
Therefore, in the present study, we designed a moderate SD model consisting of a 10-day 
SD experiment with measurements taken every 2 days until day 6, and then at day 10 for 
the histological, biochemical, and mechanical end-point assays.
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Table 3.1 Data extracted from ex vivo SD studies. N/A stands for data not available. 
Reference Model 
 
Culture 
Duration 
Results 
Short-term SD (early tendinopathy) 
Egerbacher et al,29 
2008 
Rat, Adult, Tail tendon 24 hours Biomechanical 
 None 
Histological 
 Increase in cell apoptosis 
Biochemical 
 None 
Egerbacher et al,30 
2006 
Rat, Adult, Tail tendon 24 hours Biomechanical 
 None 
Histological 
 Decrease in collagen fiber density 
38 
Biochemical 
 Increase in MMP13 expression and 
MMP13 protein synthesis 
Arnoczky, S. P. et 
al,6 2008 
Rat, Adult, Tail tendon 1,2,3 days Biomechanical 
 No change in maximum stress 
Histological 
 Cell roundness 
Biochemical 
 Increase in MMP13 expression 
Gardner et al,34 2008 Rat, 6 months old, Tail tendon 24, 48, 72 
hours 
Biomechanical 
 None 
Histological 
 None 
Biochemical 
 Increase in MMP13 expression 
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Long term-SD (advanced tendinopathy) 
Wang et al,102 2015 Rabbit, Female, 15 weeks old, 
Achilles tendon 
6,12 days Biomechanical 
 None 
Histological 
 Increase in cell apoptosis 
 Day 6: Increase in cell density; Day 12: 
Decrease in cell density 
 Cell roundness 
 Loose collagen fibers 
 Increase in space between collagen 
fibers 
 Wavy and disoriented fibers 
Biochemical 
 None 
Arnoczky et al,5 2007 Rat, Adult, Tail tendon 7 days Biomechanical 
 Decrease in ultimate stress, tensile 
modulus and strain at ultimate stress 
Histological 
 Less dense collagen fiber packing 
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Biochemical 
 Increase in MMP13 expression and 
MMP13 protein synthesis 
Abreu et al,1 2007 Rat, Male, Adult, Tail tendon 1 week Biomechanical 
 Decrease in elastic modulus 
Histological 
 None 
Biochemical 
 Decrease in GAG* content 
Lavagnino et al,49 
2005 
Rat, 13 months old, Tail tendon 21 days Biomechanical 
 None 
Histological 
 No change in collagen fiber density 
Biochemical 
 None 
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Hannafin et al,37 
1995 
Canine, Adult, mixed age and sex, 
Flexor digitorum tendon 
8 weeks Biomechanical 
 Decrease in tensile modulus 
Histological 
 Decrease in cellularity 
 Cell roundness 
 Mild increase in collagen crimps 
Biochemical 
 None 
 
*: Glycosaminoglycans: an ECM constituent.
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3.3. MATERIALS AND METHODS: 
Animals. Experiments were carried out on male Sprague Dawley rats weighing 500-800 
g (4 to 6 months old) (Charles River; St. Constant, Québec, Canada). Animal housing and 
the experimental protocol (protocol #EL2013-01) were carried out in accordance with 
regulations set by the Canadian Council of Animal Care Committee and were approved by 
the Animal Care Committee of the University of Sherbrooke (CIPA/CFPA-FMSS). 
RTT extraction. Tendon isolation and preparation were conducted as described in a 
previous study18. The distribution of rats and tendons for mechanical testings and 
viability, histology and biochemical analysis are shown in Figure 3.1. All manipulations 
were performed in a cold Dulbecco’s phosphate buffered saline (D-PBS) solution (311-
410-CL; Wisent Inc., St-Bruno, Canada) containing 1 g/L glucose (609-037-EL; Wisent 
Inc.) and 1% antibiotic–antimycotic (15240-062; Invitrogen, Burlington, Canada). 
Following isolation, tendon cross-sectional areas were evaluated using an optic 
micrometer and a stereomicroscope76. Briefly, the tendons were maintained in the saline 
solution to avoid dehydration and rotated along their longitudinal axis. Images of 
specimen projections were captured at 10° angular increments and the tendon edges were 
localized within a local reference frame using a contrast-based image analysis algorithm. 
The cross-sectional areas were estimated using a profile reconstruction algorithm. The 
tendons were then washed 5 times under sterile conditions. Afterwards, they were 
transferred to tissue culture flasks containing DMEM solution (12800-017; Invitrogen, 
Burlington, Canada) supplemented with 3.7 g/L of sodium bicarbonate (600-105-CG; 
Wisent Inc.), 10% FBS (090150; Wisent Inc.), and 1% antibiotic–antimycotic.  
RTT incubation. Tendons were divided into five groups in the core experiments and 
three groups in the secondary experiments based on culture time (Figure 3.1). In each 
experiment, fresh tendons were used as controls to the stress-deprived (SD) tendons. SD 
tendons were incubated under tissue culture conditions (37 °C, 95% humidity, 5% CO2, 
sterile environment) for 2, 4, 6, or 10 days. In the core experiments, there were three 
tendons in each group, two for mechanical testing and one for the histology and 
biochemical studies. In these experiments, the mechanical results from the two tendons 
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were averaged for each group. In the secondary experiment, there were two tendons per 
group, one for mechanical characterization and one for the histology and biochemical 
studies. The media were changed every 2 days.   
RTT mechanical characterization. Mechanical tests were conducted on live tissues at 
the end of their culture time (i.e., 0 (control), 2, 4, 6, or 10 days). At the time of mechanical 
testing, the ends of the tendon were wound around cylinder-shaped anchors and allowed 
to dry briefly on the top face of the anchors. A small drop of ethyl cyanoacrylate (10300; 
Figure 3.1 Number and distributions of tendons from each rat. RTT stands for rat tail 
tendon, and 2 Days, 4 Days, 6 Days, and 10 Days stand for 2, 4, 6, and 10 days of stress 
deprivation, respectively. In the core experiment, there were three tendons in each group, 
two for mechanical analysis, and one for viability, histology, and biochemical analyses. In 
the secondary experiment, there were two tendons per group: one for mechanical analysis 
and the other for viability, histology, and biochemical analyses. 
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Krazy Glue, Columbus, OH) was applied to the portion of the tendon at the top of the 
anchor. The tendons were then transferred to a custom-manufactured bioreactor77. The 
specimens were subjected to the following testing protocol: The initial zero-strain 
reference was defined by achieving a tension load of 3 g at equilibrium. Preconditioning 
was performed with a series of 120 sinusoidal waves at two different amplitudes (60 
cycles at 1% strain; 60 cycles at 2% strain) at 1 Hz. The final zero-strain reference was 
defined by again reaching a tension load of 3 g at equilibrium. Afterwards, the tendons 
were subjected to a traction test (at a strain rate of 0.5%/s). Maximum engineering stress 
before failure was used as a measure of tendon strength. Data are reported as normalized 
to day 0. 
Viability test. Viability tests were conducted on RT tissues at the end of their culture time 
(i.e., 0, 2, 4, 6, or 10 days). Viability of cells from the fresh and cultured tendons was 
assessed using the LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells (L3224; 
Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Tendons were 
washed in D-PBS to remove any serum and then incubated with ethidium homodimer-1 
(1 µM for 45 min) followed by treatment with calcein AM (1 µM for 40 min) in D-PBS at 
room temperature. The tendons were washed briefly in D-PBS prior to being mounted on 
glass slides. Green-fluorescing live cells and red-fluorescing dead cells were visualized 
within 45 min with an EVOS FL Auto microscope (Thermo Fisher Scientific, 
Massachusetts, USA). Images were captured with a digital camera.  
Immunofluorescence staining of MMP-13 protein. We examined MMP13 because it is 
equivalent to MMP1 (interstitial collagenase) in human and because its expression has 
been reported to be increased in pathological human tendons5. Immunohistochemical 
studies of MMP-13 were conducted on tissue samples that had been previously fixed in 
10% neutral buffered formalin (032-060, Fisher Scientific, Company LLC, Kalamazoo, MI) 
and embedded in the optimal cutting temperature (OCT)-embedding medium. Embedded 
tissues were longitudinally cut into 20 m sections using a cryostat (Thermo Scientific, 
Cheshire, UK). Sections were incubated in 0.1 M glycine (56-40-6, Roche diagnostic GmbH, 
Mannheim, Germany)/D-PBS for 10 min to wash away the mounting medium used in the 
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tissue sectioning. Sections were incubated in D-PBS/0.1% Triton (T8787, Sigma Aldrich, 
Merck KGaA, Darmstadt, Germany)/2% bovine serum albumin (BSA) (A7030, Sigma 
Aldrich, Merck KGaA, Darmstadt, Germany) at RT for 30 min inside a humid chamber. 
They were then washed once in 0.1 M glycine/D-PBS and five times in D-PBS. After 
washing, sections were incubated with the rabbit polyclonal anti-MMP13 antibody 
(ab39012, Abcam, Cambridge, UK, 20 µg/µl; all antibodies are diluted in D-PBS/0.05% 
Triton/1% BSA) and DAPI (62248, Sigma Aldrich, Oakville, Canada, 1 µg/mL) at room 
temperature for 1 h. Sections were washed five times in D-PBS and were incubated with 
the secondary antibody (A11034, Alexa Fluor 488 goat anti-rabbit IgG, Life Technologies, 
Carlsbad, California, United States; 20 µg/µl) at room temperature for 1 hour. They were 
washed in D-PBS, mounted on microscopy slides with mounting media (F4680, Sigma 
Aldrich, Oakville, Ontario, Canada) and sealed with nail polish. Negative controls included 
sections incubated with the rabbit isotype IgG antibody, (X0903, Agilent Dako, Santa Clara, 
US; 20 µg/µl, diluted in D-PBS/0.05% Triton/ 1% BSA) without being exposed to the 
primary antibody. Green (MMP-13 proteins) and blue (nucleus) fluorescence images were 
captured with an EVOS FL Auto microscope (Thermo Fisher Scientific, Massachusetts, 
USA).  
The 20X images of MMP-13 protein were analyzed using Image-Pro Plus software (version 
6.0.) to quantify the intensity of MMP-13. Three ROIs focusing on the central zones of RT 
were captured from each image. The MMP-13 intensity was calculated as the sum of the 
density of signals in each pixel from each ROI. The results from the three ROIs were 
averaged. Data are reported as normalized to day 0. 
RT-PCR analysis of MMP-13 mRNA transcript expression 
In preliminary experiments, total RNA extraction from frozen tissues was performed 
using the TRIspin method85, which combines the Trizol method with the RNeasy Total 
RNA Kit (Qiagen). RNA integrity was assessed with an Agilent RNA 6000 Nano LabChip 
according to the manufacturer’s protocol. Two micrograms of RNA from each sample was 
converted to cDNA using the Superscript First-strand RT-PCR Kit (Invitrogen) with 
random primers that were then subjected to PCR amplification using the Platimun Pfx 
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Polymerase Kit (Invitrogen). To ensure the absence of genomic DNA contamination, RT 
reactions were also conducted in the absence of reverse transcriptase (-RT). Comparative 
quantifications of MMP-13 expression levels at each time point were performed by 
quantifying their respective PCR products using an Agilent DNA 1000 Labchip and 
expressed as ratios of the amount of each MMP amplicon over that of the corresponding 
18S88. 
Histological characterization. Histological studies were conducted on RT tissues fixed 
in 10% neutral buffered formalin and embedded in either paraffin for hematoxylin and 
eosin staining or in OCT medium.  
Paraffin-embedded tissues were longitudinally sectioned into 6 µm-thick sections and 
were processed in hematoxylin and eosin (H&E) stain for light microscopy. Images of each 
sample were captured using whole slide imaging with a Nanozoomer (Hamamatsu 
Photonics K.K., Hamamatsu city, Japan) in visible mode. The 20X images were analyzed 
using the following five parameters: fiber density, areas of spaces between fibers, fiber 
tortuosity, tenocyte density and nucleus shape. 
The two first parameters of the extracellular matrix were evaluated using Image-Pro Plus 
software as described previously38. For each micrograph, three regions of interest (ROIs) 
were captured taking care not to include damages caused by the cutting blade. The ROIs 
were then analyzed with Image-Pro Plus software. Data are presented as normalized to 
day 0. 
Fiber density. The background density was found by contrast and separated into two 
categories: background (red) and fibers (black). The fiber density was calculated as:  
 𝐹𝑖𝑏𝑒𝑟 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (%) = ቀ1 − ே௨௠௕௘௥ ௢௙ ௣௜௫௘௟௦ ௢௙ ௕௔௖௞௚௥௢௨௡ௗ
ே௨௠௕௘௥ ௢௙ ௣௜௫௘௟௦ ௢௙ ோைூ
ቁ × 100 % (3.1) 
Results from the three ROIs were averaged.  
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Areas of spaces between fibers. For each ROI, the areas of the spaces between fibers were 
also evaluated in terms of pixel numbers and then averaged. Data are reported as 
normalized to day 0. 
Fiber tortuosity. For collagen fiber tortuosity analysis, digital images of H&E stained 
slides were randomly numbered for blind analysis. Fiber tortuosity was scored between 
0 and 3 using a semiquantitative scale similar to the Bonar scoring method6. 0 was 
assigned to images that showed the least collagen tortuosity (collagen fibers were mostly 
aligned in the longitudinal direction of tendon), whereas 3 was assigned to images with 
the waviest collagen fibers. Data are reported as normalized to day 0. 
Tenocyte density. Tenocyte density was evaluated as: 
 𝑇𝑒𝑛𝑜𝑐𝑦𝑡𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  ே௨௠௕௘௥ ௢௙ ௧௘௡௢௖௬௧௘௦
்௘௡ௗ௢  ௟௢௡௚௜௧௨ௗ௜௡௔௟ ௔௥௘௔
  (3.2) 
Using a grid with a known scale bar, the number of cells was counted, and the tendon 
longitudinal area was calculated. Data are reported as normalized to day 0. 
Nucleus shape. Longitudinal cryo-sections of formalin-fixed tissues of 20 µm thickness 
were stained with DAPI (DAPI, Sigma Aldrich, 62248, 1 µg/mL). Images of blue nuclei 
were captured using whole slide imaging with the Nanozoomer.  The 40X images were 
analyzed using Image-Pro Plus software. The nucleus shape was recognized by contrast, 
and its roundness was evaluated as:  
 𝑁𝑢𝑐𝑙𝑒𝑢𝑠 𝑟𝑜𝑢𝑛𝑑𝑛𝑒𝑠𝑠 =  ௉௘௥௜௠௘௧௘௥ ௢௙ ௡௨௖௟௘௨௦
మ
ସ × గ ×஺௥௘௔ ௢௙ ௡௨௖௟௘௨௦
 (3.3) 
A value of 1 indicates a perfect circle, whereas higher values indicate more elongated 
shapes. Data are reported as normalized to day 0. 
Statistical analyses 
Data are represented as the means ± standard error of mean (SEM). Mechanical, 
histological, and biochemical results were compared using nonparametric Wilcoxon 
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matched-pairs signed rank tests (GraphPad prism, 7.03) or one-median Wilcoxon tests 
(IBM SPSS) comparing groups to day 0. Significance was set at p values < 0.05. 
3.4. RESULTS 
Cross-sectional area 
The cross-sectional areas of tendons were evaluated to 0.036 ± 0.002 mm2. 
Cell Viability 
Under fluorescence microscopy, control (day 0) samples showed a high number of green 
cells and a few red cells, indicating a high level of viability (Figure 3.2a). As the SD time 
increased, samples revealed a gradual increase in the number of red cells (Figure  3.2b, c, 
d, e). Qualitative observations suggest that there was an increase in the rate of cell death 
after 6 and 10 days of SD compared to that at earlier time points (Figure 3.2d, e). 
 
Figure 3.2 Typical fluorescence micrographs obtained from freshly isolated tendons 
experiencing 2, 4, 6, and 10 days of stress deprivation. Green-fluorescing cells are alive, 
and red-fluorescing cells are dead. Bar = 200 µm. 
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Mechanical results 
The stress at failure of fresh tendons was evaluated to 5.3 ± 1.0 MPa. The effect of SD on 
the maximum stress at failure of the RTTs is demonstrated in Figure 3.3. There were no 
changes in the maximum stress at failure after 2 and 4 days of SD compared to that for the 
day 0 control. However, at 6 and 10 days of SD, there was a statistically significant 
decrease in the maximum stress at failure to approximately 40% of the initial stress at day 
0.  
Histology 
Under light microscopy, freshly harvested samples showed dense and well-aligned 
collagen fibers (Figure 3.4a). Fiber density and space area between fibers of fresh tendons 
were evaluated to 92.4 ± 0.9% and 42.5 ± 3.5 pixels, respectively. Following SD, tendons 
exhibited more loosely packed and wavy collagen fibers and had increased space between 
collagen fibers compared to the fresh control samples (Figure 3.4b-e). Moreover, under 
SD conditions, tendon cells started to lose their elongated shape and became more 
Figure 3.3 Changes in maximum stress at failure (mean and SEM) with stress deprivation. 
* indicates a significant difference (p<0.05) from day 0 (fresh tendons); +, a significant 
difference (p<0.05) from 2 days of stress deprivation; and x, a significant difference 
(p<0.05) from 4 days of stress deprivation. 
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rounded in shape (Figure 3.4b-e).  
The roundness of the nuclei of fresh tendons was evaluated to 2.3 ± 0.1. Quantitative 
analyses confirmed our qualitative observations regarding the space between fibers, fiber 
density, and nucleus shape (Figure 3.5a,b,d). There was a significant increase in the space 
between fibers at each time point compared to fresh tendons (until ~300% at day 10) on 
the basis of the quantitative analyses. Moreover, there was a significant decrease in fiber 
density after 6 and 10 days of SD compared to fresh tendons (to ~85% and ~75%, 
respectively). Nucleus roundness of tendons after 4, 6, and 10 days of SD also increased 
significantly compared to that of fresh tendons. 
The cell number of fresh tendons was found to be 251.9 ± 19.7 #cells/mm2 before 
normalization. As shown in Figure 3.5c, cell density first increased to 113% and 146% at 
days 2 and 4, respectively. The cell density then decreased to 98% and 65% at day 6 and 
10 of SD, respectively. The cell density at day 10 was significantly different from those on 
day 0 and day 4.  
Figure 3.4 Typical micrographs of longitudinal sections of tendons stained with 
hematoxylin and eosin. Bar = 100m. 
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Collagen tortuosity increased with culture time, as evaluated by the scoring technique. As 
shown in Figure 3.5e, this increase was significantly different at days 4 and 10 of SD 
compared to day 0. 
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Figure 3.5 Quantification of a) space between fibers, b) fiber density, c) cell number, d) 
nucleus elongation, and e) semiquantification of collagen tortuosity. The data are presented 
as the means and SEM. * indicates a significant difference (p<0.05) from day 0 (fresh 
tendons); and x, a significant difference (p<0.05) from 4 days of stress deprivation. 
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Biochemical results 
SD tendons demonstrated an upregulation of MMP13 with increasing SD time compared 
to fresh tendons (Figure 3.6a, and b). Epifluorescent staining data revealed that this 
upregulation was statistically significant at day 6 compared to the fresh tendons (Figure 
3.6b). However, at day 10, there was a decrease in MMP13 level to ~130% compared to 
that at the previous SD time point (day 6).  
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Figure 3.6 Biochemical analysis. a) Representative epifluorescence micrographs of 
tendons stained for MMP13 protein. Bar = 200m. b) MMP13 labeling intensity 
evaluated for freshly isolated tendons as well as tendons that experienced 2, 4, 6, 
and 10 days of stress deprivation (means and SEM). Inset. Consolidation of 
increased MMP13 in one tendon sample by PCR analysis. * indicate significant 
difference (p<0.05) from day 0 (fresh tendons). 
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3.5. DISCUSSION 
We developed an ex vivo tendinopathy model in RTTs using SD. After 4 days of SD under 
tissue culture conditions, we observed some moderate histopathologic, biochemical and 
viability changes but no changes in mechanical properties. We refer to this tendinopathy 
stage as moderate tendinopathy. This model will be useful for studying the progression of 
physiopathology in mechanobiological studies as well as for testing potential treatments 
to stop or reverse the progression of the pathology. 
 In both ex vivo and in vivo experiments, an increase in cell number has been reported in 
tendinopathic tendons33,90,96,102,108. This hypercellularity appears to be the initial response 
of tendons to activate their repair mechanism106. However, cellularity decreases with 
further progression of tendinopathy90,102. This results in an inverted-U curve relating 
cellularity with time. On this graph, we found that peak cellularity occurs at 4 days of SD, 
which we refer to as moderate tendinopathy. In contrast to these observations, in vivo SD 
of rabbit patellar tendons resulted in a progressive increase in cells over a 6-week 
period108. One reason explaining these observations could be differences in the underlying 
mechanisms of tendinopathy between ex vivo and in vivo models.   
Our observations show that biomechanical properties are affected by SD only after 
approximately 5 days of culture time. Previous ex vivo studies have reported that short-
term SD does not affect biomechanical properties, which is in accordance with our results. 
However, there is a lack of information in the literature regarding the time point at which 
this significant degradation in mechanical properties occurs. Our data suggest that 
mechanical deterioration happens between days 4 and 6 of SD. The observed delay in 
mechanical response to SD could be related to the absence of mechanical degradation, i.e., 
degradation through mechanical loading, in disuse models of tendinopathy development.  
One of the pathologic characteristics that tendons experience during tendinopathy 
development is cell apoptosis29,102,110. In agreement with the literature, we observed a 
decrease in live cells and an increase in dead cells in both short-term and long-term 
tendinopathies. However, we did not specifically look at the type of cell death. In addition 
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to the results from short- and long-term SD, the current study also provides data from 
mid-term SD. In the current study, the results from day 4 of SD confirm that there is a 
continuous increase in cell death throughout the early, moderate, and advanced 
tendinopathy stages. 
There is also evidence that tendon cells transform from an elongated shape to a round 
shape in tendinopathic tendons106, in agreement with our observations. Based on previous 
ex vivo studies, cell roundness appears only after 24 hours of SD6 and increases with 
culture time. Our data suggest that this increase in early and advanced tendinopathies is 
continuous through moderate tendinopathy as well. 
Our data suggest that in addition to cellular shape, density and viability, gene response is 
also affected by SD. In agreement with our results, increases in MMP13 (mRNA and 
protein) have been consistently reported in tendinopathy5,6,30,34,106. In the current study, 
despite the initial increase, we observed a decrease in MMP13 levels after 10 days of SD. 
This decrease may be due to a decline in cell density and/or cell viability after 10 days of 
SD.  
We observed a progressive decrease in fiber density of SD tendons from early (short-
term) to advanced (long-term) tendinopathy. This decrease in fiber density of tendons has 
also been reported in previous ex vivo studies examining short- and long-term SD5,30,102. 
An increase in the space between fibers was also reported at both time points30,102. 
Usually, changes in fiber density and the space between fibers are accompanied by 
disorganized collagen bundles106. Our data suggest a continuous decrease in collagen 
alignment through early to moderate and advanced tendinopathy.  
Currently, there is no single model available that represents all aspects of human 
tendinopathy15,27. Similar to other models, SD models have limitations. During SD, tendon 
properties are altered without exposing the tendon to mechanical loading. For this reason, 
SD models do not include simultaneous enzymatic and mechanical degradation. 
Accordingly, the model used in this study should be used with caution when investigating 
overuse injuries. SD models relate more closely to immobilization scenarios such as 
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casting or rest after surgery. Indeed, applying mechanical loads to SD tendons has been 
used to deepen our understanding of rehabilitation in these situations102. Finally, since SD 
models are easy to implement, they could be an excellent choice for studies in which 
multiple samples and conditions are needed. It should be noted that our SD system and 
obtained results were duplicable for 4-6-month-old rats. However, it is probable that 
changing the species, race, sex or age of the animals would alter some of the results, such 
as the time scale of the tendinopathy development. This could be the subject of future 
investigations. 
In conclusion, we have created a model to develop moderate tendinopathy in RTTs using 
the SD method. To our knowledge, this is the first study to characterize the moderate stage 
of tendinopathy. Our data suggest that moderate tendinopathy occurs around day 4 of 
stress deprivation. Because advanced tendinopathy can be more difficult to cure and 
because early tendinopathy is often asymptomatic, meaning that patients most likely do 
not seek medical treatment, it is reasonable to test treatments for moderate tendinopathy 
first and, if successful, to proceed with treatments for more advanced tendinopathy. Our 
study characterized a moderate stage of tendinopathy in an ex vivo SD model based on the 
viability, histopathology, biochemical, and mechanical properties of tendons. 
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Chapter 4. Efficacy of combining PRP and MMP 
inhibitors in treating moderately damaged 
tendons ex vivo  
4.1. ABSTRACT 
Platelet-rich plasma (PRP) and broad-spectrum matrix metalloproteinase inhibitors 
(MMPIs) have been used as therapeutic options for tendinopathy. However, mixed results 
have been reported regarding their efficacy. We posited that the combination of these two 
treatment strategies would be more beneficial for healing tendons than each treatment 
alone. Rat tail tendons were harvested and cultured without mechanical stress for 0, 4, or 
10 days. Single and combination treatment with PRP and MMPIs was administered to 4-
day stress-deprived (SD) tendons. This treatment was applied to the tendons over 6 days. 
At the end of their culture time, the tendons were subjected to traction testing and 
histopathological, biochemical, and viability assays. The results showed better mechanical 
and histological results for PRP+narrow-spectrum MMPIs (NI) than for PRP, NI, or broad-
spectrum MMPIs (BI) alone. The stress at failure of the PRP+NI-treated tendons was better 
than that of the 10-day SD tendons. Compared with the 10-day SD tendons, the PRP+NI-
treated tendons also had improved fiber density, nucleus shape, and space between fibers. 
This study shows that the combination of PRP with NI is a potentially effective treatment 
approach for tendinopathy.  
Keywords: platelet rich plasma; matrix metalloproteinase inhibitor; mechanical 
properties; biochemical properties; histology 
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4.2. INTRODUCTION 
Tendinopathy, a general condition of tendon disorder, is a common problem, particularly 
for athletes and workers. To date, the optimal strategy for treating tendinopathy is still 
not defined. Platelet-rich plasma (PRP) and matrix metalloproteinase inhibitors (MMPIs) 
are regarded as two promising treatments. Modeling the tendon mechanobiological 
response (TMR) as 
 TMR = Repair – (Mechanical degradation + Enzymatic degradation)22 (4.1) 
highlights that the combination of these treatments might be beneficial by enhancing 
tendon repair while inhibiting the proteolytic degradation of connective tissues. 
Administration of autologous PRP at lesion sites has been shown to promote tendon 
regeneration. This positive effect of PRP is believed to result, at least in part, from growth 
factors released from activated platelets16,93,112. 
Indeed, there is a large body of preclinical and clinical evidence supporting the beneficial 
effects of PRP therapy on tendinopathy16,20,35,43,58,59,67,93,95,97,103,104. The beneficial effects of 
PRP therapy may include tenocyte proliferation3,11,36,58,68 and improved morphology93, 
increased collagen production and organization16,43,56–58,89, increased mechanical 
strength16,43,58,93,97,104 and a better repair rate56,57,59. However, some studies did not 
observe any positive effect of PRP on damaged tendons82,87,92. It has been suggested that 
the presence of catabolic proteases such as matrix metalloproteinases (MMPs) in PRP 
could inhibit tissue healing82. 
MMPs are a family of enzymes responsible for extracellular matrix (ECM) degradation69 
and could play an important role in tendinopathy development24,78,86. An increase in the 
MMP level in tendinopathic tissue has been reported in many studies23,61,73. Therefore, 
inhibiting MMPs has been considered a potential healing approach to stop the pathological 
process of tendinopathy23,24,60. Greater collagen organization13,14,25,44,70, as well as a 
reduction in collagen degradation14,70, limited MMP activity13,25,44,70, and increased 
mechanical strength13,25,44,70, have been reported as effects of the use of broad-spectrum 
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matrix MMPIs (BI) (e.g., doxycycline and alpha-2-macroglobulin) in surgically induced 
tendinopathy models. MMPIs have also been used in clinical trials to improve tendon 
healing. The most common conditions that have been treated by injection of the MMPI 
aprotinin in clinics are Achilles, patellar, and hamstring tendinopathies73. These studies 
have yielded mixed results regarding the effectiveness of this approach9,17,19. Some studies 
have shown that broad-spectrum MMP inhibition impairs tendon healing, since some 
MMPs play a fundamental role in remodeling and healing46,54,75,79. Therefore, more 
selective inhibition might lead to positive effects. In fact, it would be beneficial to target 
specific MMPs that are detrimental to tendon healing without affecting MMPs that either 
are beneficial for tendon remodeling or cause side effects when inhibited62. This targeting 
could be achieved by applying narrow-spectrum MMPIs (NI) instead of BI. Based on the 
literature highlighting the detrimental roles of the upregulated MMP13 in the 
etiopathogenesis of tendinopathy5,6,34,75, the selection of NI was oriented towards a 
commercially available, cell-permeable, small molecule inhibitor specific to MMP13, 
referenced under CAS 204140-01-2 (IC 50=900 pM). 
Based on the above considerations, the present study was designed to investigate the 
efficacy of PRP and MMPIs (BI and NI), alone or combined, to treat moderately damaged 
tendons, i.e., 4-day stress-deprived (SD) tendons, ex vivo. Our objective was to investigate 
whether combination of PRP and MMPIs provides better results than PRP or MMPIs alone. 
4.3. MATERIALS AND METHODS 
Animals. Experiments were carried out on male Sprague-Dawley rats (4- to 6-month-old) 
(Charles River; St. Constant, Québec, Canada). Animal housing and the experimental 
protocol (protocol #EL2014-03) were carried out in accordance with regulations set by 
the Canadian Council of Animal Care Committee and were approved by the Animal Care 
Committee of the University of Sherbrooke (CIPA/CFPA-FMSS). 
Rat tail tendon (RTT) extraction. Tendon isolation and preparation were conducted as 
described in a previous study18. The distribution of rats and tendons for mechanical tests 
and viability, histological and biochemical analyses is shown in Figure 4.1. All 
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manipulations were performed in a cold Dulbecco’s phosphate-buffered saline (D-PBS) 
solution (311-410-CL; Wisent Inc., St-Bruno, Canada) containing 1 g/L glucose (609-037-
EL; Wisent Inc.) and 1% antibiotic-antimycotic (15240-062; Invitrogen, Burlington, 
Canada). Following isolation, tendon cross-sectional areas were evaluated using a custom 
optical micrometer and a stereomicroscope76. Briefly, the tendons were maintained in the 
saline solution to avoid dehydration and were rotated along their longitudinal axis. Images 
of specimen projections were captured at 10° angular increments, and the tendon edges 
were localized within a local reference frame using a contrast-based image analysis 
algorithm. The cross-sectional areas were estimated using a profile reconstruction 
algorithm. The tendons were then washed 5 times under sterile conditions. Afterwards, 
the tendons were transferred to tissue culture flasks containing DMEM solution (12800-
017; Invitrogen, Burlington, Canada) supplemented with 3.7 g/L sodium bicarbonate 
(600-105-CG; Wisent Inc.), 10% FBS (090150; Wisent Inc.), and 1% antibiotic-
antimycotic.  
RTT incubation. Tendons were divided into three main groups: 1) Fresh, 2) SD, and 3) 
treated (Figure 4.1). The fresh tendons were the newly extracted tendons. 
The SD tendons were tendons cultured without mechanical loading to create moderate or 
advanced tendinopathy. These tendons were divided into two groups and incubated in 
tissue culture conditions (37 °C, 95% humidity, 5% CO2, sterile environment) for 4 or 10 
days. The medium was changed every 2 days.  
Treated tendons were first incubated in tissue culture conditions (37 °C, 95% humidity, 
5% CO2, sterile environment). For 4 days, these tendons were cultured without 
mechanical loading to create moderate tendinopathy, and the medium was changed every 
2 days. On day 4, 1.5 MPa static loading (SL) was applied to the moderately damaged 
tendons by attaching a stainless steel weight to an approximately 11 cm long RTT in order 
to stop the progression of the tendinopathy at the time of treatment application. This 
loading amplitude was chosen based on the reported anticatabolic effect of low SL on 
tenocytes in the literature8,107 and our results from preliminary tests (data not shown). 
For 6 more days, the loaded tendons were suspended in polyethylene tubes containing 
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the mentioned culture medium with or without biochemical treatments: PRP, NI, BI, 
PRP+NI, and PRP+BI (Figure 4.1) using the following concentrations: 10 nM NI (CAS 
204140-01-2, Millipore Sigma, Ontario, Canada), 25 µM BI (CC1010, Millipore Sigma, 
Ontario, Canada), and 2.5% (vol/vol) PRP. The medium was changed once, 3 days after 
the treatment application (corresponding to day 7 of the experiment). There were two 
tendons in each subgroup, one for mechanical characterization and one for viability, 
histological and biochemical studies. 
Figure 4.1 Number and distributions of tendons from each rat. RTT stands for rat 
tail tendon. SD stands for stress-deprived. N stands for the number of rats for 
either RTT extraction or blood collection. 4 Day and 10 Day indicate 4 and 10 
days of stress deprivation, respectively. SL, P, NI, BI, P+NI, and P+BI stand for 
static loading, platelet-rich plasma (PRP), narrow-spectrum matrix 
metalloproteinase (MMP) inhibitor, broad-spectrum MMP inhibitor, 
PRP+narrow-spectrum MMP inhibitor, and PRP+broad-spectrum MMP inhibitor, 
respectively. There were two tendons in each group, one for mechanical analysis 
and the other for viability, histological, and biochemical analyses. 
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Blood collection and PRP preparation. For each experiment, whole blood was collected 
from 4 male 4-6-month-old Sprague-Dawley rats, 2 rats at day 4 and 2 rats at day 7 of the 
experiment. The rats were anesthetized with ketamine/xylazine (1 µl/g, intramuscular), 
and 12-14 ml of whole blood was collected by cannulation of the carotid artery with a 
polyethylene catheter (PE-10) containing heparinized saline solution. Blood was collected 
in Eppendorf tubes containing 3.5% sodium citrate via the carotid artery. PRP was 
obtained from blood samples by low-speed centrifugation (100g, 20 min, room 
temperature). The platelets inside the PRP were activated by adding adenosine 
diphosphate (ADP) (A2754, Sigma-Aldrich, Milwaukee, USA) to the PRP immediately 
before adding PRP to the culture medium. The activated PRP was immediately applied to 
the culture medium at a 2.5% concentration. 
Platelet counts were conducted using a hemocytometer shortly after PRP preparation. The 
required concentration was approximately 1 × 106 platelets/µl PRP. PRP samples with a 
lower platelet concentration were discarded from the experiment. 
RTT mechanical characterization. Mechanical tests were conducted on live tissues at 
the end of their culture time (i.e., day 0 for group 1, day 4 or 10 for group 2 and day 10 for 
group 3). At the time of mechanical testing, each end of the tendon was aspirated into one 
2-3 cm long silicon tube using a microvolume pipette. To prevent tendon sliding, the tubes 
were compressed using clamps and were fixed inside the testing compartment. For 
mechanical characterization, the tendons were transferred to a custom-manufactured 
bioreactor77. The specimens were subjected to the following testing protocol. The initial 
zero-strain reference value was defined as the strain when a tension load of 3 g was 
reached at equilibrium. Preconditioning was performed with a series of 120 sinusoidal 
waves at two different amplitudes (60 cycles at 1% strain; 60 cycles at 2% strain) at 1 Hz. 
The final zero-strain reference value was defined again as the strain when a tension load 
of 3 g was reached at equilibrium. Afterwards, the tendons were subjected to a traction 
test (at a strain rate of 0.5%/s). The maximum engineering stress before failure was 
reported as the measure of the tendon strength. The data normalized to the day 0 values 
are reported. 
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Viability test. Viability tests were conducted on tissue at the end of their culture time (i.e., 
day 0 for group 1, day 4 for group 2 and day 10 for group 3). The viability of cells from the 
fresh and cultured tendons was assessed using the LIVE/DEAD Viability/Cytotoxicity Kit 
for mammalian cells (L3224; Invitrogen, Carlsbad, CA). Tendons were washed in D-PBS to 
remove any serum and then incubated with ethidium homodimer-1 (1 µM for 45 min) 
followed by treatment with calcein AM (1 µM for 40 min) in D-PBS at room temperature. 
The tendons were washed briefly in D-PBS prior to mounting on glass slides. Green-
fluorescing live cells and red-fluorescing dead cells were visualized within 45 min with an 
EVOS FL Auto microscope (Thermo Fisher Scientific, Massachusetts, USA) and recorded 
with a digital camera.  
Immunofluorescence staining of MMP13 protein. Immunohistochemical studies of 
MMP13 were conducted on tissue samples previously fixed in 10% neutral buffered 
formalin (032-060, Fisher Scientific Inc., Kalamazoo, MI) and embedded in optimal cutting 
temperature (OCT) embedding medium. The embedded tissues were longitudinally 
sectioned to 20 µm thickness using a cryostat (Thermo Scientific, Cheshire, UK). The 
sections were incubated in D-PBS containing 0.1 M glycine (56-40-6, Roche Diagnostic 
GmbH, Mannheim, Germany) for 10 min to wash away the mounting medium used for 
tissue sectioning. The sections were incubated in D-PBS containing 0.1% Triton (T8787, 
Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) and 2% bovine serum albumin (BSA) 
(A7030, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) at room temperature (RT) for 
30 min inside a humid chamber. The sections were then washed once with D-PBS 
containing 0.1 M glycine and five times with D-PBS. Subsequently, the sections were 
incubated in rabbit polyclonal anti-MMP13 antibody (ab39012, Abcam, Cambridge, UK, 
20 µg/µl, all antibodies were diluted in D-PBS containing 0.05% Triton and 1% BSA) and 
DAPI (62248, Sigma-Aldrich, Oakville, Canada, 1 µg/ml) at RT for 1 hour. The sections 
were washed five times with D-PBS and were incubated in secondary antibody (A11034, 
Alexa Fluor 488 goat anti-rabbit IgG, Life Technologies, Carlsbad, California, USA; 20 
µg/µl) at room temperature for 1 hour. After further washing in D-PBS, sections were 
incubated in D-PBS containing 0.1% Triton and 2% BSA at room temperature for 10 min. 
The sections were then washed in D-PBS, mounted on microscopy slides with mounting 
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medium (F4680, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany), and sealed with nail 
polish. The negative controls were sections incubated with rabbit isotype IgG antibody 
(X0903, Agilent Dako, Santa Clara, USA; 20 µg/µl, diluted in D-PBS containing 0.05% 
Triton and 1% BSA) without being exposed to primary antibody. Green (MMP13 proteins) 
and blue (nucleus) fluorescence images were captured with the EVOS FL Auto microscope 
(Thermo Fisher Scientific, Massachusetts, USA).  
The 20× images of MMP13 protein were analyzed with Image-Pro Plus software (version 
6.0.0) to quantify the MMP13 intensity. From each image, three regions of interests (ROIs) 
were selected, taking care to exclude the tendon periphery (which usually has saturated 
signals). The MMP13 intensity was calculated as the summation of the signal densities 
signals in each pixel of each ROI. The results from the three ROIs were averaged. 
Histological characterization. Histological studies were conducted on biopsies that 
were taken from each tissue, fixed in 10% neutral buffered formalin and embedded in 
either paraffin for hematoxylin and eosin (H&E) staining or in OCT medium.  
Paraffin-embedded biopsies were longitudinally cut into 6 µm-thick sections and were 
processed in H&E stain for light microscopy observation. Images of each sample were 
captured using a NanoZoomer whole slide imaging system (Hamamatsu Photonics K.K., 
Hamamatsu, Japan) in visible mode. The 20× images were analyzed using the following 
five parameters: fiber density, areas of the spaces between fibers, fiber tortuosity, 
tenocyte density and nucleus shape. 
The two first parameters of the ECM were evaluated using Image-Pro Plus software as 
described previously38. For each micrograph, three ROIs were captured taking care to 
exclude regions damaged by the cutting blade. The ROIs were then analyzed with Image-
Pro Plus software. Data normalized to day 0 are presented. 
Fiber density. The background density was found by contrast and separated into two 
categories: background (red) and fibers (black). The fiber density was calculated as:  
 𝐹𝑖𝑏𝑒𝑟 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 (%) = (1 − ே௨௠௕௘௥ ௢௙ ௣௜௫௘௟௦ ௢௙ ௕௔௖௞௚௥௢௨௡ௗ
ே௨௠௕௘௥ ௢௙ ௣௜௫௘௟௦ ௢௙ ோைூ
) * 100% (4.2) 
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The results from the three ROIs were averaged.  
Areas of the spaces between fibers. For each ROI, the areas of the spaces between fibers 
were also evaluated in terms of pixel number and then averaged. Data normalized to day 
0 are reported. 
Tenocyte density. Tenocyte density was evaluated as: 
 𝑇𝑒𝑛𝑜𝑐𝑦𝑡𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  ே௨௠௕௘௥ ௢௙ ௧௘௡௢௖௬௧௘௦
்௘௡ௗ௢௡ ௟௢௡௚௜௧௨ௗ௜௡௔௟ ௔௥௘௔
  (4.3) 
Using a grid and the known scale bar, the number of cells were counted, and the tendon 
longitudinal area was calculated.  
Nucleus shape. Longitudinal cryo-sections of formalin-fixed biopsies 20 µm in thickness 
were stained with DAPI (DAPI, Sigma-Aldrich, 62248, 1 µg/ml) (as described in the 
biochemical characterization section). Images of blue nuclei were captured using the 
NanoZoomer whole slide imaging system. The 40× images were analyzed using Image-Pro 
Plus software. The nucleus shape was recognized by contrast, and its roundness was 
evaluated as:  
 𝑁𝑢𝑐𝑙𝑒𝑢𝑠 𝑟𝑜𝑢𝑛𝑑𝑛𝑒𝑠𝑠 =  ௉௘௥௜௠௘௧௘௥ ௢௙ ௡௨௖௟௘௨௦
మ
ସ∗గ∗஺௥௘௔ ௢௙ ௡௨௖௟௘௨௦
  (4.4) 
A value of 1 indicates a perfect circle, whereas higher values indicate more elongated 
shapes. Data normalized to day 0 are reported. 
References for comparison 
We chose three references to evaluate the results of the applied treatments: 1) Fresh 
tendons as they represent the optimal goal for tissue repair; 2) 4-day SD tendons 
(tendinopathic models)39 as they represent the tissue state we treated and wanted to 
improve; and 3) 10-day SD tendons as they represent the progression of the untreated 
tendinopathic model that should at least be improved by the treatments. In other words, 
the optimal treatment would improve the tendinopathic tendons to the quality level of 
fresh tendons. At the other end of the spectrum, a less optimal treatment should not 
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degrade the tendinopathic tendons to a state worse than 10-day SD tendons. Other 
treatments, such as stabilizing or slowing down the degradation, would be classified in 
between these effects. 
Statistical analyses 
Data are presented as the mean ± standard error of the mean (SEM). Biomechanical, 
histological, and biochemical results were compared using nonparametric Wilcoxon 
matched-pairs signed rank tests (GraphPad prism, 7.03) or one-sample Wilcoxon tests 
(IBM SPSS) comparing the groups to day 0. Significance was set at p values <0.05. 
4.4. RESULTS 
Cross-sectional area 
The cross-sectional areas of the tendons were calculated to be 0.037 ± 0.002 mm2 (mean 
± SEM). 
Platelet concentration 
The platelet concentration within PRP was evaluated to be 1.36 ± 0.09 x 106 platelets/µl. 
Cell viability 
Figure 4.2 shows representative fluorescence micrographs of the tendons. Fresh samples 
(group 1) showed a high number of green cells and a few red cells, indicating a high level 
of viability. As the time of the SD increased (group 2), i.e., 4-day SD and then 10-day SD, 
the number of red cells in the samples gradually increased.  
For treated tendons (group 3), qualitative observations suggest that the cell viability was 
comparable to that of the 4-day SD tendons. No evident differences were observed 
between the treated tendons. 
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Figure 4.2 Representative fluorescence micrographs of tendons in the various treatment 
groups. Abbreviations as in figure 1. Green-fluorescing cells are alive, and red-fluorescing 
cells are dead. Bar=200 µm. 
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Mechanical result 
The maximum stress at failure of fresh tendons was evaluated to be 8.54 ± 0.83 MPa (mean 
± SEM). Consistent with our previous result (unpublished data), on day 10, the stress at 
failure of the SD RTTs (group 2) decreased significantly to ~ 65% of the value for fresh 
tendons (Figure 4.3). For the treated tendons (group 3), the stress at failure of the PRP+NI-
treated tendons was ~ 95% of the value for fresh tendons. This treatment was the only 
treatment that improved the mechanical strength of our tendinopathic model to a value 
better than that of 10-day SD tendons (p=0.1). The other treatments resulted in a 
reduction in the stress at failure to ~ 50% or less relative to that of the fresh tendon.  
Histology 
The fiber density and the space area between fibers of the fresh tendons were evaluated 
to be 94 ± 1%, and 54.9 ± 8.6 pixels (mean ± SEM), respectively. Under a light microscope, 
freshly harvested samples showed dense and well-aligned collagen fibers (Figure 13). 
Compared to fresh tendons, the 4-day SD tendons showed a significantly lower fiber 
density and a larger space area between fibers (Figure 13 and Figure 14a and b). A further 
decrease in fiber density and an increase in the space between fibers was observed in the 
10-day SD tendons (group 2) compared to the fresh and 4-day SD tendons. These changes 
 
Figure 4.3 Changes in maximum stress at failure (mean and SEM). Abbreviations as in figure 1. * 
indicates p<0.05 compared to fresh tendons, and + indicates p=0.1 compared to 10-day SD.  
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relative to the fresh tendons were significant. In the treated tendons (group 3), the SL-, 
PRP-, and NI-treated tendons showed significantly lower fiber density than fresh tendons. 
Compared to the 4-day SD tendons, none of the treated tendons had significantly different 
fiber density or space between fibers. However, compared to the 10-day SD group, the 
PRP- and PRP+NI-treated groups had a significant improvement in fiber density. 
Moreover, the space between fibers was significantly lower in the PRP+NI-treated group 
than in the 10-day SD group (Figure 4.4, and 4.5a and b). 
 
 
 
 
Figure 4.4 Typical micrographs of longitudinal sections of tendons stained with 
hematoxylin and eosin. Abbreviations as in figure 1. Bar=100 µm 
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The cell number of fresh tendons was evaluated to be 220 ± 21 cells/mm2. The cell density 
was significantly higher in 4-day SD tendons than in fresh tendons (Figure 4.5c). However, 
in 10-day SD tendons, the cell density returned to  104% of the cell density observed in 
fresh tendons (Figure 4.5c). The cell density of 10-day SD tendons did not differ 
significantly from that of 4-day SD or fresh tendons. In the treated tendons (group 3), only 
the PRP+BI treatment resulted in a significant increase in cell density relative to that in 
fresh tendons. The other treatments did not significantly change the cell density from that 
in fresh or 4-day SD tendons. Compared to 10-day SD tendons, PRP- and PRP+BI-treated 
tendons had significantly higher cell density (Figure 4.5c). 
The nuclear roundness of fresh tendons was evaluated to be 2.34 ± 0.16 (mean ± SEM). 
Compared to the cells in fresh tendons, the cells in both 4- and 10-day SD tendons became 
significantly less elongated and became round (Figure 4.5d). In group 3, the SL-, NI-, and 
PRP+BI-treated tendons also showed significantly rounder cells than the fresh tendons. 
None of the treatments caused the shape of the tenocytes to differ significantly from the 
shape of the cells in 4-day SD tendons. However, compared to the 10-day SD tendons, the 
SL-, PRP-, and PRP+NI-treated tendons had a significantly more elongated cell shape 
(Figure 4.5d). 
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Figure 4.5 Quantification of the a) space between fibers, b) fiber density, c) cell number, and d) 
nucleus elongation. Abbreviations as in figure 1. The data are presented as the mean and SEM. * 
indicates a significant difference (p<0.05) compared with fresh tendons; x, a significant 
difference (p<0.05) compared with 10-day SD tendons. 
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Biochemical results 
The 4-day SD tendons had an approximately similar MMP13 level as the fresh tendons 
(Figure 4.6). However, in the 10-day SD tendons, the MMP13 level significantly decreased 
to ~ 48% of the MMP13 level of fresh tendons. None of the treatments resulted in 
significant changes in the MMP13 level comparing to those of the fresh, 4-, or 10-day SD 
tendons. While the MMP13 level of all treated groups remained approximately 250% or 
less, the MMP13 level of the PRP-treated group was found to be ~ 800%. 
 
 
 
 
 
Figure 4.6 Biochemical analysis. MMP13 labeling intensity evaluated for freshly isolated tendons, 
SD tendons and treated tendons (mean and SEM). Abbreviations as in figure 10. * indicates p<0.05 
compared to fresh tendons. 
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4.5. DISCUSSION 
We investigated the efficacy of PRP and MMPIs (BI and NI) alone and in combination using 
an ex vivo model of moderate tendinopathy. We showed that PRP combined with a 
narrow-spectrum MMP inhibitor is more efficient in treating moderate tendinopathy ex 
vivo than PRP or MMPIs alone. Moreover, our data suggest a trend for better histological 
and mechanical results with NI than with BI, when NI or BI are combined with PRP. 
The improved healing by the combination of PRP and MMPIs is probably associated with 
a simultaneous improvement in regeneration (i.e., molecular events resulting in matrix 
synthesis and tissue repair) and inhibition of selected degeneration processes (i.e., events 
resulting in matrix degradation). Comparing the results from PRP+NI and PRP+BI reveals 
that cell number and nucleus shape of PRP+NI-treated tendons are comparable to those 
of healthy tendons but not PRP+BI-treated ones. This observation together with the 
mechanical results could reflect a synergistic effect between PRP and NI. However, further 
studies are needed to demonstrate and understand the effect.  
There has been growing evidence indicating that using NI rather than BI would lead to 
greater efficacy and less adverse effects in different diseases, such as cancers and 
arthritis12,62,109. Although the exact mechanisms of these BI-induced side effects are poorly 
understood, it has been suggested that the lack of selectivity of these inhibitors could be a 
reason109.  
It has already been shown that PRP could have beneficial effects in treating tendinopathy, 
but the results varied. PRP has some catabolic and inflammatory effects on tendon cells, 
such as catabolic protease (e.g., MMP) production, which might be detrimental to tissue 
healing82,113. 
For PRP-treated tendons compared to 10-day SD tendons, our data revealed improved 
fiber density and tenocyte morphology. Despite these improvements in histology, no 
improvement in the mechanical properties of PRP-treated tendons was observed. In the 
literature, there are some discrepancies regarding mechanical results. Virchenko et al. 
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reported the positive effect of PRP on the mechanical properties of a rat Achilles tendon 
subjected to surgically induced tendinopathy after only 3 and 5 days of PRP treatment in 
vivo97. However, in most in vivo studies, PRP-treated tendinopathic tendons, which had 
either surgically induced16,43,58,93 or collagenase-induced20 tendinopathy, exhibited 
improved mechanical properties after 2 weeks or more but not at earlier time points43,104. 
Therefore, it is possible that 6 days was not sufficient for PRP to improve the mechanical 
properties and that mechanical improvement could have happened at later times.  
Inhibiting MMPs (broadly and selectively) has also been considered as a therapeutic 
option for tendinopathy23,24,60. However, in this study, MMPIs (either NI or BI) alone did 
not improve the mechanical or histological properties of tendons. It should be noted that 
most of the studies that reported beneficial effects of MMPIs on tendon healing were 
conducted in vivo with tendinopathy created through surgical intervention13,14,25,44,70. This 
condition might explain the difference between our results and those studies. Moreover, 
in most studies, the tendons were analyzed at day 7 or a few weeks after drug application. 
Therefore, it is possible that the 6-day culture time in this study was not sufficient for the 
MMPIs to show efficacious results. 
The mechanical results show that compared to 4-day SD tendons, low SL tendons had a 
lower maximum stress (p=0.1). This finding contradicts our presumption and previous 
reports in the literature, i.e., the application of low SL maintains tendon properties1,107. 
However, it should be noted that unlike studies in the literature, which examined the effect 
of low SL on fresh samples, we have applied SL to damaged tendons. It has been theorized4 
that partial collagen tears in damaged tendons prevent the tendons from properly 
transferring an external load to cells. The resulting understimulated cells produce more 
degeneration than repair. One might think that increasing the amount of SL would 
increase the load amount perceived by cells and could stop enzymatic degradation. 
However, in our preliminary tests, higher loads (2.5 MPa) led to tendon breaking in less 
than 48 hours. One possible solution could be applying higher SL with some rest periods. 
This process would probably trigger the cell repair response (SL) while minimizing 
mechanical degradation (rest periods).  
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In this study, we showed that PRP combined with NI is a potentially effective treatment 
for healing tendinopathy and leads to better mechanical and histological properties than 
the traditional use of PRP or MMPIs alone. These results suggest that PRP and NI 
combination therapy may be clinically useful. Further studies could investigate the effect 
of exposing tendons with chronic tendinopathy to a combination of PRP and NI for longer 
times, as well as applying an SL higher than 1.5 MPa with rest periods between loading 
episodes. Obviously, in vivo application of PRP and NI combination therapy is necessary 
to support the findings of this ex vivo research study. 
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Chapter 5. Conclusion 
5.1. Summary  
Tendon disorders are common health problems. They can affect several aspects of 
people’s life from daily to work-related activities. Although, many strategies have been 
suggested to treat tendinopathy, none of them was completely satisfactory. Developing 
animal tendinopathy models (in vivo and ex vivo) not only would help to better 
understanding the pathology behind tendon damage, but also to find an optimal treatment 
for the disease.  
We decided to characterize an ex vivo model in this study, considering our lab expertise 
and equipment. Moreover, in ex vivo models, unlike in vivo models, there are less 
difficulties regarding developing and reproducing the tendinopathy model. This is 
because, in ex vivo models, there is no need to interact with animal recurrently to make 
them exercise, for instance. Therefore, these models are cheaper and less time consuming. 
However, in vivo models could be the next step following ex vivo tendinopathy induction, 
since they are more complete and closer to the human context. 
Among all available methods to develop tendinopathy ex vivo, we chose stress deprivation. 
Although SD models have already been used to create tendinopathy, there was a lack of 
knowledge regarding moderate stage of damage. Moderate stage of tendinopathy is 
crucial specially when it comes to investigating the efficacy of treatments. On the one 
hand, early stage of human tendinopathy is often asymptomatic48,65. On the other hand, 
advanced tendinopathy could be difficult to treat with non-surgical treatments. This is 
because of some irreversible pathological features such as cell apoptosis. Therefore, 
moderate tendinopathy could be optimal level of damage to investigate the efficacy of 
treatments.  
To treat tendinopathy, a combination of PRP and MMPI was proposed in this study. These 
methods were chosen based on their promising results in the literature. Moreover, 
modeling the tendon mechanobiological response (TMR) as 
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 TMR = Repair – (Mechanical degradation + Enzymatic degradation)22 (5.1) 
indicates that promoting repair via PRP, and inhibiting MMP-mediating degeneration via 
MMPI at the same time seem a complementary approach toward regaining tendon health. 
Our results indicated 4 days of SD is needed to characterize a moderate tendinopathy 
model, and combination of NI and PRP are the best when comparing to NI, BI, PRP, and 
combination of BI and PRP. 
5.2. Original contribution 
In the first part of this study (article 1), we characterized a SD model ex vivo. We observed 
some moderate pathologic changes in RTTs’ histological, biochemical, and mechanical 
properties after 4 days of SD. These changes include increases in the space between fibers, 
cell density, and collagen tortuosity and a decrease in collagen density and elongation of 
cell nuclei. No alterations in the stress at failure of tendons were observed in the moderate 
stage of damage. It should be noted that the changes in these properties grew 
progressively from day 4 until day 10, except for cell density, and stress at failure. We 
observed a drop in cell density and stress at failure between days 4 and 6 of SD. This model 
will be useful for studying the progression of physiopathology in mechanobiological 
studies as well as for investigating the efficacy of treatments to stop or reverse the 
tendinopathy progression. 
To our knowledge, this is the first study to characterize moderate stage of tendon damage. 
Moreover, for the first time, a combination of MMPI and PRP was a suggested as a 
treatment strategy.  
In the second part of this study (article 2), we applied MMPI (NI or BI) and PRP, in 
combination or alone, on created moderate tendinopathy model ex vivo. Moreover, to stop 
the degradative effects of SD, we applied a low static load on all treated tendons. After 6 
days of RTTs culture under treatments conditions, combination of PRP and NI resulted in 
superior histological and mechanical properties comparing to other treatments, and to 
non-treated condition.  
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We perceived a potential synergistic effect of combining PRP and MMPIs. We also 
observed an improvement in stress at failure, fiber density, nucleus shape and space 
between fibers in treated tendons comparing to untreated ones. 
Finally, during the progression of this project, we developed a new method to fix the 
tendons inside bioreactor chambers (not presented in this thesis) in order to achieve 
more reliable and comparable results. This method consists of the aspiration of tendon’s 
extremities inside silicon tubes, and their compression in the related anchoring system. 
This new method has the advantage of reducing stress concentration on tendons over the 
old method, which consisted of gluing tendon’s extremities around spools. 
5.3. Future work 
In order to advance the results of this study toward clinical treatments, four strategies 
could be implemented. 
5.3.1 Developing tendinopathy using the ex vivo model with some 
modifications 
To further validate the efficacy of our suggested combination therapy on tendinopathy, 
we could develop a tendinopathy model ex vivo, with following modifications: 
Using SD model ex vivo, while changing some parameters such as: species, age, race, 
or sex of the animal 
The results of our study regarding development of moderate tendinopathy, and the effect 
of applied treatments on moderate tendinopathic tendon, were duplicable for tail tendons 
of 4-6 months old male Sprague-Dawley rats. Changing the species, tendon, age, race, or 
sex of the animal might change some of the results, for example the time point of the 
moderate tendinopathy development or the treatment efficiency. As an example, we 
observed in preliminary studies that tendons from older rats seem to respond less 
efficiently to the treatments (data note presented in this thesis). Moreover, it has been 
suggested that there is a difference between men and women in terms of the risk of 
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tendinopathy development 32 and also respond to treatments, because alternative 
mechanisms may be involved80. In addition, genetic differences between different races 
and species might affect their load resistance. For example, HCR rats, which have high 
endurance running capacity, will probably develop moderate tendinopathy in later time 
points. 
Changing the method of tendinopathy development ex vivo 
During SD, tendon properties degrade without exposing the tendon to mechanical loading. 
Therefore, SD models do not represent simultaneous enzymatic and mechanical 
degradation. For this reason, SD models relate more closely to immobilization scenarios 
such as casting or rest after surgery rather than overuse injuries. A subject of future 
studies could be developing overuse (ex: in the bioreactor), or surgically-induced 
tendinopathy rather than underuse (SD), and testing the combination of PRP and MMPIs 
on these.   
5.3.2 Developing tendinopathy using an in vivo model.  
Although ex vivo methods create well-defined tendinopathy models, in vivo models are 
essential to study the effects of other systems of whole body on tendon pathology and 
healing and therefore to gain a more complete understanding of the tendinopathy under 
real conditions. For example, vascularization, which may affect tendon repair, is absent in 
ex vivo models. Therefore, in vivo animal studies should be conducted to provide a better 
understanding of tendinopathy and to test the effect of combination of PRP and MMPIs on 
different types of injury (SD, overuse, acute).  
5.3.3. Developing different stages of tendinopathy ex vivo or in vivo 
Applying our suggested combination therapy on more advanced stages of tendinopathy, 
ex vivo or in vivo, could be another subject of future studies. It is possible that the 
treatment efficiency changes with tendinopathy stages, since the level of damages and 
cells mechanostat set points also changes. 
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5.3.4. Modifying amount and/or time point of SL application on ex vivo 
tendinopathy model 
In our experiments, exposing damaged tendons to treatments at the same time as applying 
SL on them, resulted in inferior mechanical results comparing to 10 day non-treated 
samples.  
Applying SL with a delay to other treatments i.e., MMPI and/or PRP, could also be an 
interesting subject of future studies to improve the treatment strategy for tendinopathy. 
In this way, MMPI and/or PRP could help develop an ECM which could transfer, and 
respond to loads more properly, before exposing tendons to SL.  
Finally, a more fundamental study to better understand the interaction of cell and ECM 
would be to applying higher amounts of SL, to reset mechanostat set point of the cells, 
while allowing some rest periods between loading episodes. According to the literature, 
this method would cause cell repair response, while minimizing mechanical degradation 
due to rest periods.   
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Conclusion (en francais) 
Les affections aux tendons sont des problèmes de santé courants. Ils peuvent toucher 
plusieurs aspects de la vie des gens, des activités quotidiennes aux activités 
professionnelles. Bien que de nombreuses stratégies aient été suggérées pour traiter les 
tendinopathies chroniques, aucune n’était complètement satisfaisante. Des modèles 
animaux de tendinopathies (in vivo et ex vivo) aiderait non seulement à mieux comprendre 
la pathologie des lésions tendineuses, mais aussi à trouver un traitement optimal pour 
cette affection. 
Dans cette étude, nous avons décidé de caractériser un modèle ex vivo, en tenant compte 
de notre expertise et de notre équipement en laboratoire. De plus, dans les modèles ex 
vivo, contrairement aux modèles in vivo, il est plus facile de développer et de reproduire 
le modèle de tendinopathie. C'est parce que, dans les modèles ex vivo, il n'est pas 
nécessaire d'interagir avec l'animal de manière récurrente pour le faire s'exercer, par 
exemple. Par conséquent, ces modèles sont moins chers et prennent moins de temps. 
Cependant, les modèles in vivo pourraient être la prochaine étape après induction de la 
tendinopathie ex vivo, car ils sont plus complets et plus proches du contexte humain. 
Parmi toutes les méthodes disponibles pour développer une tendinopathie ex vivo, nous 
avons choisi la privation de chargement mécanique. Bien que les modèles de privation de 
chargement aient déjà été utilisés pour créer des tendinopathies, il y avait un manque de 
connaissances concernant le stade modéré des dommages. Le stade modéré de la 
tendinopathie est crucial, surtout lorsqu'il s'agit d'étudier l'efficacité des traitements. 
D'une part, le stade précoce de la tendinopathie humaine est souvent 
asymptomatique48,65. En revanche, les tendinopathies avancées peuvent être difficiles à 
traiter. Par conséquent, une tendinopathie modérée pourrait être un niveau optimal de 
dommage pour étudier l'efficacité des traitements. 
Pour traiter la tendinopathie, une combinaison de PRP et de IMPMs a été proposée dans 
cette étude. Ces traitements ont été choisies en fonction de leurs résultats prometteurs 
83 
dans la littérature. En outre, la modélisation de la réponse mécanobiologique du tendon 
(RMT),  
RMT = Réparation - (dégradation mécanique + dégradation enzymatique)22 , 
indique que la promotion de la réparation par la PRP et l'inhibition de la dégénération 
médiée par la métalloprotéase via le IMPM semblent être une approche complémentaire 
pour retrouver la santé des tendons. Nos résultats indiquent que 4 jours de SD sont 
nécessaires pour caractériser un modèle modéré de tendinopathie et que la combinaison 
de IÉ et de PRP est la meilleure par rapport à IÉ, IL, PRP et à la combinaison de IÉ et de 
PRP. 
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Appendix 
A.1 Matrix metalloproteinases  
The enzymes which are capable of breaking down the proteins into their smaller 
components such as peptides or amino acids are called proteinases. Matrix 
metalloproteinases (MMPs) are a family of proteinases, responsible for extracellular 
matrix (ECM) degradation69.   There are more than 20 MMPs identified which are 
subdivided on the basis of their substrates into several groups: collagenases, gelatinases, 
stromelysins, membrane type MMPs (MT-MMPs), and other members that do not fit 
properly in these groups99. 
The main function of MMPs is to degrade ECM molecules69. However ECM degradation 
could lead to further biological activities which consequently affect non-ECM molecules 
too69. The effect of MMPs on ECM, and non-ECM molecules could be constructive such as: 
wound healing and bone growth and development, or destructive such as: tumor invasion 
and arthritis61.  
MMP’s activity is inhibited by tissue inhibitors of metalloproteinases (TIMPs). In normal 
condition, i.e. when MMPs and TIMPs are balanced, MMPs activity results in tissue 
developing, remodeling and repair. However, when the balance between MMPs and their 
inhibitors is dysregulated, MMPs activity causes damage in tissue. Therefore, the balance 
between MMP and TIMP activity is crucial to tissue homeostasis69. 
A.2 Nucleus shape 
Figure A.2.1 shows representative of fresh and 10-day SD nucleus stained with DAPI 
(DAPI, Sigma-Aldrich, 62248, 1 µg/ml).  
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Using Image-Pro Plus software, the nucleus shape was traced automatically, based on the 
contrast. The roundness of nucleus was measured using “roundness” tool with the 
following formula:  
 𝑁𝑢𝑐𝑙𝑒𝑢𝑠 𝑟𝑜𝑢𝑛𝑑𝑛𝑒𝑠𝑠 =  ௉௘௥௜௠௘௧௘௥ ௢௙ ௡௨௖௟௘௨௦
మ
ସ∗గ∗஺௥௘௔ ௢௙ ௡௨௖௟௘௨௦
  (A.1) 
A value of 1 indicates a perfect circle, whereas higher values indicate more elongated 
shapes.  
 
 
 
  
Figure A.2.1 Typical micrographs of longitudinal sections of fresh and 10 day SD tendons 
stained with DAPI. Bar=100 µm fresh and 10-day SD tendons of DAPI stained nucleus.  
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